id_x,ticker,date,title,url,id_y,link_id,summary
1,89bio,2024-03-12,89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis,https://ir.89bio.com/news-releases/news-release-details/89bio-initiates-phase-3-enlighten-fibrosis-trial-pegozafermin,1,1,89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis. The co-primary endpoints will be assessed at week 52 and are intended to support a filing for accelerated approval in the U.S. and conditional approval in Europe.
2,89bio,2024-03-08,89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4),https://ir.89bio.com/news-releases/news-release-details/89bio-announces-inducement-grant-under-nasdaq-listing-rule-0,2,2,89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis. The co-primary endpoints will be assessed at week 52 and are intended to support a filing for accelerated approval in the U.S. and conditional approval in Europe.
3,89bio,2024-03-05,89bio to Participate in the Leerink Partners Global Biopharma Conference,https://ir.89bio.com/news-releases/news-release-details/89bio-participate-leerink-partners-global-biopharma-conference,3,3,89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis. The co-primary endpoints will be assessed at week 52 and are intended to support a filing for accelerated approval in the U.S. and conditional approval in Europe.
4,Acumen Pharmaceuticals,2024-03-12,Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days,https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-participate-stifel-2024-cns-days,4,4,"Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease. Management will participate in a fireside chat as part of the Stifel 2024 CNS Days on Tuesday, March 19, 2024, at 12:00 p.m. ET. The live webcast may be accessed under the Investors tab on www.acumenpharm.com."
5,Acumen Pharmaceuticals,2024-03-08,Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting,https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-presents-sabirnetug-acu193-fluid,5,5,"Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting. Key findings include Improvements in biomarkers associated with AD pathology, including significantly lowered CSF neurogranin and pTau181 levels."
6,Acumen Pharmaceuticals,2024-02-21,Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting,https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-present-sabirnetug-acu193-fluid-biomarker,6,6,Acumen Pharmaceuticals to present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting. ACU193 is the first humanized monoclonal antibody to demonstrate selective target engagement of AβOs.
7,Alto Neuroscience,2024-03-11,"Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors",https://investors.altoneuroscience.com/news/news-details/2024/Alto-Neuroscience-Appoints-Maha-Radhakrishnan-M.D.-to-Board-of-Directors/default.aspx,7,7,"Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) announced the appointment of Maha Radhakrishnan, M.D., to the company’s board of directors. Maha recently served as group senior vice president and chief medical officer of Biogen, responsible for the worldwide medical function, until March 2024."
8,Alto Neuroscience,2024-03-07,Alto Neuroscience to Participate in Upcoming Investor Conferences,https://investors.altoneuroscience.com/news/news-details/2024/Alto-Neuroscience-to-Participate-in-Upcoming-Investor-Conferences/default.aspx,8,8,"Alto Neuroscience, Inc. (“Alto”) today announced that company management will participate in the following upcoming investor conferences. The fireside chats will be available via live webcast on the Events and Presentations page in the Investors section of Alto’s website."
9,Alto Neuroscience,2024-02-27,Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference,https://investors.altoneuroscience.com/news/news-details/2024/Alto-Neuroscience-to-Present-at-the-TD-Cowen-44th-Annual-Healthcare-Conference/default.aspx,9,9,"Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) announced that Amit Etkin, M.D., Ph.D. will present a company overview at the TD Cowen 44th Annual Healthcare Conference on March 5, 2024. The presentation will be available via live webcast on the Events and Presentations page in the Investors section of Alto’s website."
10,Alto Neuroscience,2024-03-20,Stifel 2024 Virtual CNS Days,https://investors.altoneuroscience.com/events-and-presentations/event-details/2024/Stifel-2024-Virtual-CNS-Days/default.aspx,10,10,"To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below."
11,Alto Neuroscience,2024-03-18,UBS Virtual CNS Day 2024,https://investors.altoneuroscience.com/events-and-presentations/event-details/2024/Alto-Neuroscience-Inc--UBS-Virtual-CNS-Day-2024/default.aspx,11,11,"To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below."
12,Alto Neuroscience,2024-03-05,TD Cowen 44th Annual Health Care Conference,https://investors.altoneuroscience.com/events-and-presentations/event-details/2024/TD-Cowen-44th-Annual-Health-Care-Conference/default.aspx,12,12,"To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below."
13,ASLAN Pharmaceuticals,2024-03-13,ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering,https://ir.aslanpharma.com/news-releases/news-release-details/aslan-pharmaceuticals-announces-5-million-registered-direct,13,13,"ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN) announced today that it has entered into a definitive agreement for the purchase and sale of 5,000,000 of the Company’s American Depositary Shares (“ADSs”) The closing of the offering is expected to occur on or about March 14, 2024, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering."
14,ASLAN Pharmaceuticals,2024-03-11,ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients,https://ir.aslanpharma.com/news-releases/news-release-details/aslan-pharmaceuticals-provides-trek-dx-study-update-and,14,14,"TREK-DX, the first randomized, double-blind, placebo-controlled study to be conducted in a dupilumab-experienced atopic dermatitis (AD) patient population, has started enrolling patients in the US under an updated protocol. New European sites are on track to open in the first half of 2024. Topline unblinded data from the full dataset is expected at the end of 2024Translational data demonstrates differentiated effects of targeting IL-13R versus IL-4R, suggesting eblasakimab has the potential to be effective in AD patients."
15,ASLAN Pharmaceuticals,2024-03-06,ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors,https://ir.aslanpharma.com/news-releases/news-release-details/aslan-pharmaceuticals-announces-new-translational-data,15,15,"ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN) announced new positive translational data from a head-to-head study of eblasakimab versus dupilumab in a human tissue model of chronic obstructive pulmonary disease. The Company announced the appointment of respiratory experts Dr Ramaswamy Krishnan, MS MPhil PhD, and Dr Reynold Panettieri Jr, MD, to ASLAN’s Scientific Advisory Board."
16,Corbus Pharmaceuticals,2024-03-12,Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update,https://ir.corbuspharma.com/press-releases/detail/409/corbus-pharmaceuticals-reports-fourth-quarter-and-year-end,16,16,"Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the fourth quarter of 2023 and year-ended 2023. First patient expected to be dosed in US Ph1 study by end of March 2024."
17,Elevation Oncology,2024-03-06,Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements,https://investors.elevationoncology.com/2024-03-06-Elevation-Oncology-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Highlights-Recent-Business-Achievements,17,17,"Elevation Oncology, Inc. (Nasdaq: ELEV) announced financial results for the quarter and full-year ended December 31, 2023, and highlighted recent business achievements. EO-3021: A differentiated antibody-drug conjugate (ADC) for the treatment of patients with advanced, unresectable or metastatic solid tumors likely to express Claudin 18.2.HER3-ADC: A HER3-targeting ADC for thetreatment of solid tumors."
18,Elevation Oncology,2024-03-05,Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024,https://investors.elevationoncology.com/2024-03-05-Elevation-Oncology-to-Present-Preclinical-Proof-of-Concept-Data-for-HER3-ADC-Program-at-the-American-Association-for-Cancer-Research-AACR-Annual-Meeting-2024,18,18,"Elevation Oncology, Inc. will present preclinical proof-of-concept data for its differentiated HER3-targeting antibody-drug conjugate (ADC) program in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024."
19,Elevation Oncology,2024-03-04,"Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors","https://investors.elevationoncology.com/2024-03-04-Elevation-Oncology-Appoints-Experienced-Clinical-Development-Leaders-Julie-Cherrington,-Ph-D-and-Alan-Sandler,-M-D-to-Board-of-Directors",19,19,"Elevation Oncology, Inc. (Nasdaq: ELEV) announced the appointments of Julie Cherrington, Ph.D. and Alan Sandler, M.D., to its Board of Directors. Dr. Cherrington is an experienced life science executive with extensive insight in bringing novel product candidates into the clinic and through to commercialization."
20,Inozyme,2024-03-12,Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights,https://investors.inozyme.com/news-releases/news-release-details/inozyme-pharma-reports-full-year-2023-financial-results-and,20,20,"We use cookies to personalize content and ads, provide social media features, and, analyze our traffic. We also share information about your use of our site with our social media, advertising and analytics partners, who may combine it with other information that you’ve provided to them. View our Privacy Policy for more information."
21,Inozyme,2024-02-26,Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference,https://investors.inozyme.com/news-releases/news-release-details/inozyme-pharma-participate-td-cowen-44th-annual-health-care,21,21,"We use cookies to personalize content and ads, provide social media features, and, analyze our traffic. We also share information about your use of our site with our social media, advertising and analytics partners, who may combine it with other information that you’ve provided to them. View our Privacy Policy for more information."
22,Inozyme,2024-02-06,Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),https://investors.inozyme.com/news-releases/news-release-details/inozyme-pharma-reports-inducement-grants-under-nasdaq-listing-5,22,22,"We use cookies to personalize content and ads, provide social media features, and, analyze our traffic. We share information about your use of our site with our social media, advertising and analytics partners, who may combine it with other information that you’ve provided to them. View our Privacy Policy for more information."
23,Inspirna,2016-06-15,"Rgenix Raises $33M, Preps Cancer Trial For Drug Shelved By GSK",https://inspirna.com/rgenix-raises-33m-preps-cancer-trial-for-drug-shelved-by-gsk/,23,23,"Inspirna, Inc. is a privately-held clinical-stage biopharmaceutical. company focused on the discovery and development of novel cancer drugs. The company's drugs target key pathways in cancers of high unmet need. Inspirna is based in Long Island City, New York."
24,Inspirna,2016-06-15,"Rottweiler tested, Novo and Sofinnova back $33M round for Rgenix",https://inspirna.com/rottweiler-tested-novo-and-sofinnova-back-33m-round-for-rgenix/,24,24,"Inspirna, Inc. is a privately-held clinical-stage biopharmaceutical company. The company is focused on the discovery and development of novel cancer drugs that target key pathways in cancers of high unmet need. Rgenix is a publicly-held company."
25,Inspirna,2016-06-15,Rgenix Announces $33 Million Series B Financing to Develop First-in-Class Cancer Therapeutics,https://inspirna.com/rgenix-announces-33-million-series-b-financing-to-develop-first-in-class-cancer-therapeutics-2/,25,25,"Rgenix announced a $33 million Series B financing led by Novo A/S and Sofinnova Partners. The financing will support clinical development of Rgenix’s lead drug candidates, RGX-104 andRGX-202, as well as further development of its therapeutics pipeline."
26,Inspirna,2015-08-31,"In New York, Rgenix Rises From Rockefeller and Takes Aim at Cancer",https://inspirna.com/in-new-york-rgenix-rises-from-rockefeller-and-takes-aim-at-cancer/,26,26,"Inspirna, Inc. is a privately-held clinical-stage biopharmaceutical. company focused on the discovery and development of novel cancer drugs. The company's drugs target key pathways in cancers of high unmet need. Inspirna is based in Long Island City, New York."
27,Inspirna,2024-01-04,Inspirna to Present at the 42nd Annual J.P. Morgan Healthcare Conference,https://inspirna.com/inspirna-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference/,27,27,"Inspirna, Inc. is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs. Inspirna’s lead drug candidate, ompenaclid (RGX-202), is an orally-administered small molecule that targets the CKB/SLC6A8 pathway."
28,Inspirna,2024-01-04,"Inspirna Partners with Merck KGaA, Darmstadt, Germany, to Accelerate Global Development of Ompenaclid (RGX-202)",https://inspirna.com/inspirna-partners-with-merck-kgaa-darmstadt-germany-to-accelerate-global-development-of-ompenaclid-rgx-202/,28,28,Ompenaclid (RGX-202) is a first-in-class oral inhibitor of the creatine transport channel SLC6A8. It is currently in development for RAS mutated (RASm) second-line (2L) advanced or metastatic colorectal cancer (mCRC) Inspirna will receive an upfront payment of $45 million.
29,Inspirna,2023-10-23,Inspirna Announces Clinical Data from Phase 1b/2 Study of Ompenaclid (RGX-202) in Advanced Colorectal Cancer at ESMO Congress 2023,https://inspirna.com/inspirna-announces-clinical-data-from-phase-1b-2-study-of-ompenaclid-rgx-202-in-advanced-colorectal-cancer-at-esmo-congress-2023/,29,29,"Ompenaclid (RGX-202) in combination with FOLFIRI and bevacizumab (BEV) in RAS-mutated (RASm) advanced or metastatic colorectal cancer (CRC) presented at the European Society for Medical Oncology (ESMO) Congress 2023 being held October 20-24, 2023 in Madrid, Spain. Inspirna hosted a virtual KOL panel on Sunday, October 22, to discuss these clinical data."
30,Inspirna,2023-10-16,Inspirna to Present Clinical Data from Phase 1b/2 Study of Ompenaclid (RGX-202) in Advanced Colorectal Cancer at ESMO Congress 2023,https://inspirna.com/inspirna-to-present-clinical-data-from-phase-1b-2-study-of-ompenaclid-rgx-202-in-advanced-colorectal-cancer-at-esmo-congress-2023/,30,30,"Inspirna, Inc. announced today that data from the ongoing Phase 1b/2 study of ompenaclid (RGX-202) in combination with FOLFIRI and bevacizumab (BEV) in RAS-mutated (RASm) advanced or metastatic colorectal cancer (CRC) will be presented at the European Society for Medical Oncology (ESMO) Congress 2023. Inspirna will host a virtual KOL panel to discuss the data on Sunday, October 22, 2023 at 12:30pm ET. A webcast of the event will be available on the “Events and Presentations"
31,Inspirna,2023-06-01,Inspirna to Present at the Jefferies Healthcare Conference,https://inspirna.com/inspirna-to-present-at-the-jefferies-healthcare-conference/,31,31,"Inspirna, Inc. is a clinical stage biopharmaceutical company developing first-in-class cancer therapeutics. Chief Executive Officer Dr. Usman “Oz” Azam, M.D., will participate in a corporate presentation at the Jefferies Healthcare Conference on June 8, 2023 at 1:30pm ET."
32,Inspirna,2023-05-01,"Inspirna Appoints Dr. Usman “Oz” Azam, M.D., as New Chief Executive Officer",https://inspirna.com/inspirna-appoints-dr-usman-oz-azam-m-d-as-new-chief-executive-officer/,32,32,"Inspirna appoints Dr. Usman “Oz” Azam, M.D., as its new Chief Executive Officer. Co-founder Masoud Tavazoie steps down as Chief Executive officer and Director. Dr. Azam brings over two decades of drug development experience."
33,Inspirna,2023-01-05,Inspirna Announces Interim Data from Phase 1b/2 Study of Abequolixron (RGX-104) in Relapsed or Refractory Lung Cancer,https://inspirna.com/inspirna-announces-interim-data-from-phase-1b-2-study-of-abequolixron-rgx-104-in-relapsed-or-refractory-lung-cancer/,33,33,"Abequolixron (RGX-104) is a first-in-class, small molecule liver X receptor (LXR) agonist designed to target APOE dysregulation and enhance anti-tumor immunity. The drug candidate could be a valuable addition to a current standard of care chemotherapy in heavily-pretreated patients with lung cancer."
34,Inspirna,2022-11-17,Inspirna to Present at the Evercore ISI Annual HealthCONx Conference,https://inspirna.com/inspirna-to-present-at-the-evercore-isi-annual-healthconx-conference/,34,34,"Inspirna, Inc. is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs. The company is pursuing several first-in-class drug candidates. Its lead drug candidate, RGX-202, is an orally-administered small molecule that targets the CKB/SLC6A8 pathway."
35,Inspirna,2022-07-11,Inspirna Raises $50 Million in Series D Financing,https://inspirna.com/inspirna-raises-50-million-in-series-d-financing/,35,35,"Inspirna, Inc. announced that it has raised $50 million in a Series D financing round. New investors Sands Capital and Vivo Capital, with additional participation from new investor Dreavent 6. Existing investors also participated in the financing round including Novo Holdings A/S, Sofinnova Partners, Sixty Degree Capital Fund."
36,Inspirna,2022-06-28,Inspirna to Present Phase 1b RGX-202-01 Clinical Trial Data at the 2022 ESMO World Congress on Gastrointestinal Cancer,https://inspirna.com/inspirna-to-present-phase-1b-rgx-202-01-clinical-trial-data-at-the-2022-esmo-world-congress-on-gastrointestinal-cancer/,36,36,"RGX-202-01 is an oral, potential first-in-class small molecule inhibitor of SLC6a8, a creatine transporter that drives colorectal cancer and certain other cancers’ progression. The drug is also very well-tolerated, enabling a safe and effective combination therapy with FOLFIRI/BEV to provide further optionality for patients."
37,Inspirna,2022-05-26,Inspirna to Present Phase 1b RGX-202-01 Clinical Trial Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting,https://inspirna.com/inspirna-to-present-phase-1b-rgx-202-01-clinical-trial-data-at-the-2022-american-society-of-clinical-oncology-asco-annual-meeting/,37,37,"RGX-202-01 is an oral, potential first-in-class small molecule inhibitor of SLC6a8, a creatine transporter that drives colorectal cancer and certain other cancers’ progression. It is currently being evaluated in a Phase 1b dose escalation and expansion study in combination with FOLFIRI/BEV. The primary endpoint of the study is to determine maximum tolerated dose (MTD), overall response rate (ORR), and treatment-emergent adverse events (TEAEs)"
38,Inspirna,2022-04-27,Inspirna Announces Phase 1b RGX-202 Clinical Trial Data Selected for Poster Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting,https://inspirna.com/inspirna-announces-phase-1b-rgx-202-clinical-trial-data-selected-for-poster-presentation-at-the-2022-american-society-of-clinical-oncology-asco-annual-meeting/,38,38,"Inspirna, Inc. will present a poster at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7 in Chicago, Illinois. Inspirna’s lead drug candidate RGX-202 is an orally-administered small molecule that targets the CKB/SLC6A8 pathway."
39,Inspirna,2022-04-07,Inspirna to Present at 21st Annual Needham Virtual Healthcare Conference,https://inspirna.com/inspirna-to-present-at-21st-annual-needham-virtual-healthcare-conference/,39,39,"Inspirna, Inc. is a privately-held clinical-stage biopharmaceutical company. The company is pursuing several first-in-class drug candidates to treat cancers of need. CEO Masoud Tavazoie will present at the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022."
40,Inspirna,2022-03-08,Inspirna to Participate in Multiple Virtual Healthcare Investor Conferences in March,https://inspirna.com/inspirna-to-participate-in-multiple-virtual-healthcare-investor-conferences-in-march/,40,40,"Inspirna, Inc. is a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics. CEO Masoud Tavazoie, M.D., Ph.D. will participate in multiple virtual healthcare investor conferences taking place during the month of March."
41,Inspirna,2021-12-09,Inspirna Strengthens Scientific Advisory Board with Two Globally Renowned Experts in Gastrointestinal Oncology,https://inspirna.com/inspirna-strengthens-scientific-advisory-board-with-two-globally-renowned-experts-in-gastrointestinal-oncology/,41,41,"Inspirna, Inc. announced today the appointment of Josep Tabernero, M.D., Ph.D. and Alan P. Venook, M,D., to its scientific advisory board. Dr. Taberneo is the Director of the Vall d’Hebron Institute of Oncology (VHIO) and Head of the Medical oncology Department of Vall d'Hebrons University Hospital. Dr Venook is the Madden Family Distinguished Professor of Medical Oncologist and Associate Director for Development at the University of California, San Francisco."
42,Inspirna,2021-11-22,Inspirna to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference,https://inspirna.com/inspirna-to-present-at-the-piper-sandler-33rd-annual-virtual-healthcare-conference/,42,42,"Inspirna, Inc. is a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics. CEO Masoud Tavazoie will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference at 10:00 A.M. EST on November 22, 2021."
43,Inspirna,2021-11-10,Inspirna to Present at the Stifel 2021 Virtual Healthcare Conference,https://inspirna.com/stifel-2021-virtual-healthcare-conference/,43,43,"Inspirna, Inc. will present at the Stifel 2021 Virtual Healthcare Conference at 10:40 A.M. EST on November 17, 2021. To view this virtual presentation, live, register for the event here. Inspirna identifies novel cancer targets using its RNA-based target discovery platform, RNA-DRIVErTM."
44,Inspirna,2021-11-04,Inspirna Announces Clinical Collaboration with Bristol Myers Squibb to Study RGX-104 in Combination with Yervoy® (ipilimumab) for Treatment of Metastatic Endometrial Cancer,https://inspirna.com/inspirna-announces-clinical-collaboration-with-bristol-myers-squibb-to-study-rgx-104-in-combination-with-yervoy-ipilimumab-for-treatment-of-metastatic-endometrial-cancer/,44,44,"Inspirna, Inc. announced a collaboration with Bristol Myers Squibb on a clinical trial of a combination therapy using RGX-104 (abequolixron), the Company’s small molecule agonist of the Liver X Receptor/Apolipoprotein E (“LXR/APOE”) pathway, and Yervoy (ipilimumab) The study will focus on patients with metastatic endometrial cancer whose genomes possess the E2 or E4 APOE genetic biomarker."
45,Inspirna,2021-09-30,RGENIX Announces Company Name Change to Inspirna and Expands Board of Directors with Appointment of Pharma Veteran Dieter Weinand,https://inspirna.com/rgenix-announces-company-name-change-to-inspirna-and-expands-board-of-directors-with-appointment-of-pharma-veteran-dieter-weinand/,45,45,"Inspirna, Inc., a privately-held biopharmaceutical company, announced today its corporate name change from Rgenix to Inspirna. The company also announced the appointment of Dieter Weinand to its Board of Directors, where he will serve as Chairman. Mr. Weinand, formerly CEO of Bayer Pharma AG, brings over 30 years of experience across the pharmaceutical and biotechnology industries."
46,Inspirna,2020-11-23,RGENIX to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference,https://inspirna.com/rgenix-to-present-at-piper-sandler-32nd-annual-virtual-healthcare-conference/,46,46,"Rgenix, Inc. is a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics. CEO Masoud Tavazoie, M.D., will present at the 32nd Annual Piper Sandler Virtual Healthcare Conference."
47,Inspirna,2020-11-04,RGENIX to Present at 2020 Stifel Virtual Healthcare Conference,https://inspirna.com/rgenix-to-present-at-2020-stifel-virtual-healthcare-conference/,47,47,"RGENIX, Inc. is a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics. CEO Masoud Tavazoie, M.D., Ph.D. will present at the 2020 Stifel Virtual Healthcare Conference on November 16, 2020."
48,Inspirna,2020-09-02,RGENIX to Present at H.C. Wainwright 22nd Annual Global Investment Conference,https://inspirna.com/rgenix-to-present-at-h-c-wainwright-22nd-annual-global-investment-conference/,48,48,"Rgenix will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020. The company is pursuing several first-in-class drug candidates to treat cancers of high unmet need. RGENIX identifies novel cancer targets using a microRNA based target discovery platform."
49,Inspirna,2020-08-05,RGENIX to Present at Multiple Virtual Healthcare Investor Conferences in August,https://inspirna.com/rgenix-to-present-at-multiple-virtual-healthcare-investor-conferences-in-august/,49,49,"RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that it has been selected to present at multiple virtual healthcare investor conferences. These conferences include: LifeSci Partners Summer Symposium, Wedbush PacGrow Healthcare Conference, and Canaccord Genuity 40th Annual Growth Conference."
50,Inspirna,2020-06-22,RGENIX Presents Biomarker and Efficacy Results from Phase 1 Dose Escalation Cohorts of RGX-104 at the 2020 AACR Annual Meeting,https://inspirna.com/rgenix-presents-biomarker-and-efficacy-results-from-phase-1-dose-escalation-cohorts-of-rgx-104-at-the-2020-aacr-annual-meeting/,50,50,The abstract was accepted for the 2020 American Association for Cancer Research (AACR) Annual Meeting. The abstract results will be presented as a virtual poster presentation (#LB-133/7) in the Late-Breaking Research: Clinical Research 1 session. RGX-104 is a small-molecule LXR agonist that modulates innate immunity via transcriptional activation of the ApoE gene.
51,Inspirna,2020-06-22,RGENIX Presents Results from Preclinical Safety and Efficacy Studies of RGX-019 at the 2020 AACR Annual Meeting,https://inspirna.com/rgenix-presents-results-from-preclinical-safety-and-efficacy-studies-of-rgx-019-at-the-2020-aacr-annual-meeting/,51,51,"RGENIX, Inc. is presenting an abstract on RGX-019, its pre-clinical antibody program in development. The abstract was accepted for the 2020 American Association for Cancer Research (AACR) Annual Meeting. The results will be presented as a virtual poster presentation (LB-090) during the Late-Breaking Research: Immunology 1 session."
52,Inspirna,2020-05-29,RGENIX Shows Clinical Activity of Novel Agent RGX-202 in Patients with KRAS Mutant Colorectal Cancer in Phase 1 Trial,https://inspirna.com/rgenix-shows-clinical-activity-of-novel-agent-rgx-202-in-patients-with-kras-mutant-colorectal-cancer-in-phase-1-trial/,52,52,RGX-202 is a first-in-class small molecule that inhibits a novel cancer metabolism pathway involved in supplying energy to cancer cells. The SLC6a8/CKB pathway was discovered using RGENIX’s proprietary miRNA-based target-discovery platform applied to KRAS mutant CRC.
53,Inspirna,2020-05-21,RGENIX To Present RGX-202 Phase I Data at 2020 ASCO Virtual Scientific Program,https://inspirna.com/rgenix-to-present-rgx-202-phase-i-data-at-2020-asco-virtual-scientific-program/,53,53,"Rgenix will present an oral abstract related to the RGX-202 program at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. The meeting is scheduled to take place May 29 – 31, 2020. RGENIX identifies novel cancer targets using a microRNA based target discovery platform. The company is pursuing several first-in-class drug candidates to treat cancers of high unmet need."
54,Inspirna,2020-04-27,RGENIX Presents Initial Results of Combination Trial of RGX-104 at the 2020 AACR Annual Meeting,https://inspirna.com/rgenix-presents-initial-results-of-combination-trial-of-rgx-104-at-the-2020-aacr-annual-meeting/,54,54,"RGX-104 is a small-molecule LXR agonist that modulates innate immunity via transcriptional activation of the ApoE gene. The safety profile was consistent with the individual profiles of RGx-104 and docetaxel, with neutropenia the most common drug-related adverse event observed. The results support further development of this regimen."
55,Inspirna,2020-02-26,Clinical Development of First-in-class Innate IO Agents,https://inspirna.com/clinical-development-of-first-in-class-innate-io-agents/,55,55,"The sixth IO360 conference in New York City gathers key representatives from industry, non-profits, regulatory bodies, investors and patients. Stakeholders will present and contrast strategies in IO from a scientific, clinical and regulatory viewpoint. Masoud Tavazoie, CEO of RGENIX, will present rationale and development strategies for novel modalities impacting the innate immune system."
56,Inspirna,2019-12-13,Rgenix Cancer Therapeutics Company Focuses on RNA to Identify Novel Targets,https://inspirna.com/rgenix-cancer-therapeutics-company-focuses-on-rna-to-identify-novel-targets/,56,56,"Inspirna, Inc. is a privately-held clinical-stage biopharmaceutical company. The company is focused on the discovery and development of novel cancer drugs that target key pathways in cancers of high unmet need. For confidential support call the Samaritans on 08457 90 90 90, visit a local Samaritans branch or see www.samaritans.org."
57,Inspirna,2019-10-16,Featured on In Vivo: “Rgenix: A Cancer Start-Up’s Resolve To Crack The Mystery Of Metastasis”,https://inspirna.com/featured-on-in-vivo-rgenix-a-cancer-start-ups-resolve-to-crack-the-mystery-of-metastasis/,57,57,"Rgenix, a New York-based start-up co-founded by three prominent physician researchers, is taking aim at what it contends is the future of cancer treatment. The company is focused on the discovery and development of novel cancer drugs that target key pathways in cancers of high unmet need."
58,Inspirna,2019-09-16,Rgenix Names Industry Veteran to Chief Medical Officer Role,https://inspirna.com/rgenix-names-industry-veteran-to-chief-medical-officer-role/,58,58,"Robert Wasserman, MD, joins Rgenix with more than 20 years of oncology clinical development experience and prior senior roles in the biopharma industry. Dr. Wasserman will oversee new Phase 1b/2 trial of lead compound RGX-104 in lung cancer patients."
59,Inspirna,2019-04-03,Rgenix Presents Pre-Clinical Data on RGX-019 at the  2019 AACR Annual Meeting,https://inspirna.com/rgenix-presents-pre-clinical-data-on-rgx-019-at-the-2019-aacr-annual-meeting/,59,59,Rgenix Presents Pre-Clinical Data on RGX-019 at the  2019 AACR Annual Meeting. Pre-clinical data demonstrates first-in-class MERTK selective inhibitor with novel mechanism of action. Rgenix has initiated IND-enabling studies of RGx-019.
60,Inspirna,2019-04-01,Rgenix To Present Abstract on RGX-019 at the 2019 AACR Annual Meeting,https://inspirna.com/rgenix-to-present-abstract-on-rgx-019-at-the-2019-aacr-annual-meeting/,60,60,"Rgenix, Inc. will present an abstract about Rgenix’s RGX-019 program at the 2019 American Association for Cancer Research Annual Meeting. The meeting is scheduled to take place Friday, March 29 through Wednesday, April 3 in Atlanta. Dr. Isabel Kurth, Ph.D., will present data from pre-clinical research of RGX -019."
61,Inspirna,2019-02-01,Translational and Clinical Development Strategies for IO Agents Targeting the Innate Immune System,https://inspirna.com/translational-and-clinical-development-strategies-for-io-agents-targeting-the-innate-immune-system/,61,61,Immuno-Oncology 360° brings together diverse stakeholders of drug development in immuno-oncology (IO) Dr. Tavazoie’s talk will highlight strategies to support the translation of preclinical data into the clinic specifically for modalities targeting the innate immune system.
62,Inspirna,2018-12-14,Xconomy: New York Biotech – How to make it here,https://inspirna.com/new-york-biotech-how-to-make-it-here/,62,62,"Rgenix, Inc. is a privately-held clinical-stage biopharmaceutical company. The company is focused on the discovery and development of novel cancer drugs. Rgenix has $40M in Series C funding and is based in Long Island City, New York."
63,Inspirna,2018-11-30,Rgenix CEO Masoud Tavazoie Discusses Immune System Regulation in Cancer at Plenary Session during AACR Meeting,https://inspirna.com/rgenix-ceo-masoud-tavazoie-discusses-immune-system-regulation-in-cancer-at-plenary-session-during-aacr-meeting/,63,63,Rgenix CEO Masoud Tavazoie Discusses Immune System Regulation in Cancer at Plenary Session during AACR Meeting. The LXR/ApoE pathway was discovered as a cancer pathway by Rgenix founding scientists utilizing an unbiased experimental approach to identify key drivers of cancer progression.
64,Inspirna,2018-11-27,Rgenix Appoints Serial Entrepreneur and Senior Executive Peter Van Vlasselaer to Board of Directors,https://inspirna.com/rgenix-appoints-serial-entrepreneur-and-senior-executive-peter-van-vlasselaer-to-board-of-directors/,64,64,"Peter Van Vlasselaer, Ph.D., is a serial entrepreneur and most recently the President and CEO of ARMO Biosciences, which he also founded. Rgenix identifies novel cancer targets using a microRNA-based target discovery platform. The company is pursuing several first-in-class drug candidates for cancers of high unmet need."
65,Inspirna,2018-11-27,AACR Tumor Immunology and Immunotherapy Conference,https://inspirna.com/aacr-tumor-immunology-and-immunotherapy-conference/,65,65,"Inspirna, Inc. is a privately-held clinical-stage biopharmaceutical. company focused on the discovery and development of novel cancer drugs. Inspirna's drugs target key pathways in cancers of high unmet need. The company is based in Long Island City, New York."
66,Inspirna,2018-10-31,Rgenix Treats First Patient in Phase 1 Trial of RGX-202,https://inspirna.com/rgenix-treats-first-patient-in-phase-1-trial-of-rgx-202/,66,66,"Rgenix, Inc. has treated the first patient in a Phase 1 a/b study of RGX-202, an oral small molecule being developed for the treatment of gastrointestinal cancers. Rgenix identifies novel cancer targets using a microRNA-based target discovery platform. The company is funded by leading biotechnology investors."
67,Inspirna,2018-10-09,Rgenix Raises $40M in Series C Funding To Support Clinical Stage Oncology Programs,https://inspirna.com/rgenix-raises-40m-in-series-c-funding-to-support-clinical-stage-oncology-programs/,67,67,"Rgenix, Inc. announced that it has raised $40 million in a Series C financing in support of further development of the company’s clinical and pre-clinical oncology programs. The financing will support Phase 1b/2 clinical trials of the lead program RGX-104 in multiple cancer indications, including in checkpoint inhibitor refractory patients. The company is pursuing several first-in-class drug candidates to treat cancers of high unmet need."
68,Inspirna,2018-06-04,Rgenix Presents Data on Phase I Clinical Activity For RGX-104 at the 2018 ASCO Annual Meeting,https://inspirna.com/rgenix-presents-data-on-phase-i-clinical-activity-for-rgx-104-at-the-2018-asco-annual-meeting/,68,68,"Rgenix is presenting data on the safety, pharmacodynamics, and clinical activity from the dose escalation stage of the ongoing Phase Ia/b trial of RGX-104. The small molecule depletes myeloid derived suppressor cells (MDSCs) and stimulates dendritic cells (DCs), activating anti-tumor immunity."
69,Inspirna,2018-05-31,Rgenix To Present Data on RGX-104 Clinical Activity at  2018 ASCO Annual Meeting,https://inspirna.com/rgenix-to-present-data-on-rgx-104-clinical-activity-at-2018-asco-annual-meeting/,69,69,Rgenix will present its abstract on RGX-104’s pharmacodynamic and clinical activity at the 2018 Annual Meeting of the American Society of Clinical Oncology. The meeting will take place in Chicago from June 1 through June 5. Rgenix identifies novel cancer targets using a microRNA based target discovery platform.
70,Inspirna,2018-05-25,"Pharmacodynamic and clinical activity of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies",https://inspirna.com/pharmacodynamic-and-clinical-activity-of-rgx-104/,70,70,"RGX-104 is a small-molecule LXR agonist that modulates innate immunity via transcriptional activation of the ApoE gene. To read the abstract, please click here.Inspirna, Inc. is a privately-held clinical-stage biopharmaceutical company."
71,Inspirna,2018-01-11,Rgenix Announces Publication In Cell Demonstrating Activation of LXR/ApoE with RGX-104 Enhances Antitumor Immunity,https://inspirna.com/rgenix-announces-publication/,71,71,"Rgenix, Inc. announced today the publication of clinical and pre-clinical results by research collaborators at Rgenix and The Rockefeller University. The results of the collaboration, published in the January 11 online issue of Cell, reveal that the Liver-X Receptor/Apolipoprotein E (LXR/ApoE) pathway regulates anti-tumor immunity."
72,Inspirna,2017-11-17,Liver X Factor,https://inspirna.com/liver-x-factor/,72,72,"Rgenix’s Liver X Agonist Could Help Overcome Checkpoint Resistance in Cancer. Rgenix is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs. To read the full article, please click here."
73,Inspirna,2017-11-17,Rgenix Reports Phase I Data for Cancer Compound RGX-104,https://inspirna.com/rgenix-reports-phase-i-data-for-cancer-compound-rgx-104-2/,73,73,"Rgenix Inc. (New York, N.Y.) reported preliminary data from a Phase Ia/Ib trial showing that oral RGX-104 led to 4 cases of stable disease among 12 evaluable patients with advanced solid malignancies and lymphoma. To read the full article, please click here."
74,Inspirna,2017-10-30,Rgenix Reports Preliminary Phase 1a/b Clinical Data Demonstrating Immune-stimulatory Activity with RGX-104 in Advanced Cancer Patients,https://inspirna.com/rgenix-reports-preliminary-phase-1a-b-clinical-data-2/,74,74,Preliminary Phase 1a/b data demonstrate RGX-104 modulates the innate immune system to stimulate T cell activation in a diverse group of heavily pre-treated patients. The company presented the data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia.
75,Inspirna,2017-10-29,Rgenix Reports Preliminary Phase 1a/b,https://inspirna.com/rgenix-reports-preliminary-phase-1a-b/,75,75,Preliminary Phase 1a/b data demonstrate RGX-104 modulates the innate immune system to stimulate T cell activation in a diverse group of heavily pre-treated patients with refractory solid cancers. The company presented the data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia.
76,Inspirna,2017-10-26,Rgenix to Present Early Clinical Data on RGX-104 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics,https://inspirna.com/rgenix-to-present-early-clinical-data-on-rgx-104/,76,76,"Rgenix, Inc. is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs. The company is pursuing several first-in-class drug candidates to treat cancers of high unmet need. Dr. Monica Mita, Principal Investigator of the RGX-104-001 study, will present at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics."
77,Inspirna,2017-10-09,Meet the 30 biotech leaders under 40 who are searching for breakthrough treatments and shaping the future of medicine,https://inspirna.com/meet-the-30-biotech-leaders-under-40/,77,77,"Meet the 30 biotech leaders under 40 who are searching for breakthrough treatments and shaping the future of medicine. To read the full piece, please click here. Visit inspirna.com for more information about Inspirna, a privately-held clinical-stage biopharmaceutical company."
78,Inspirna,2017-09-14,"For Rgenix CEO Masoud Tavazoie, fighting cancer is a family business",https://inspirna.com/for-rgenix-ceo-masoud-tavazoie-fighting-cancer-is-a-family-business/,78,78,"Rgenix CEO Masoud Tavazoie was recently interviewed for an article in The Pharma Letter. To read the full piece, please click here. Rgenix is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs."
79,Inspirna,2017-04-28,Rgenix Appoints Chief Medical Officer,https://inspirna.com/rgenix-appoints-chief-medical-officer/,79,79,"Rgenix, Inc. announced today the appointment of Roger Waltzman, M.D., M.B.A. as its Chief Medical Officer. Dr. Waltzman brings more than 20 years of experience in oncology across the entire new drug development and approval process. He will oversee clinical development, including clinical trial design and the new drug application process with regulators."
80,Inspirna,2017-01-06,"Rgenix Announces Treatment of First Patient in Phase 1 Trial of RGX-104, its Lead Immuno-Oncology Therapeutic",https://inspirna.com/rgenix-announces-treatment-of-first-patient-in-phase-1-trial-of-rgx-104/,80,80,Rgenix announces treatment of the first patient with its lead candidate RGX-104 in a Phase 1a/b study. The 80-patient study consists of an initial dose-escalation stage involving patients with advanced solid malignancies and lymphoma. The LXR-ApoE pathway was originally identified as a cancer target using a novel microRNA-based discovery platform.
81,Inspirna,2016-06-29,What does it take to succeed as a New York biotech startup?,https://inspirna.com/rgenix-announces-33-million-series-b-financing-to-develop-first-in-class-cancer-therapeutics/,81,81,"Inspirna, Inc. is a privately-held clinical-stage biopharmaceutical. company focused on the discovery and development of novel cancer drugs. The company is based in Long Island City, New York City. Inspirna is developing drugs that target key pathways in cancers of high unmet need."
82,Inspirna,2016-06-15,"Rgenix Raises $33M, Preps Cancer Trial For Drug Shelved By GSK",https://inspirna.com/rgenix-raises-33m-preps-cancer-trial-for-drug-shelved-by-gsk/,82,82,"Inspirna, Inc. is a privately-held clinical-stage biopharmaceutical. company focused on the discovery and development of novel cancer drugs. The company's drugs target key pathways in cancers of high unmet need. Inspirna is based in Long Island City, New York."
83,Inspirna,2016-06-15,"Rottweiler tested, Novo and Sofinnova back $33M round for Rgenix",https://inspirna.com/rottweiler-tested-novo-and-sofinnova-back-33m-round-for-rgenix/,83,83,"Inspirna, Inc. is a privately-held clinical-stage biopharmaceutical company. The company is focused on the discovery and development of novel cancer drugs that target key pathways in cancers of high unmet need. Rgenix is a publicly-held company."
84,Inspirna,2016-06-15,Rgenix Announces $33 Million Series B Financing to Develop First-in-Class Cancer Therapeutics,https://inspirna.com/rgenix-announces-33-million-series-b-financing-to-develop-first-in-class-cancer-therapeutics-2/,84,84,"Rgenix announced a $33 million Series B financing led by Novo A/S and Sofinnova Partners. The financing will support clinical development of Rgenix’s lead drug candidates, RGX-104 andRGX-202, as well as further development of its therapeutics pipeline."
85,Inspirna,2015-08-31,"In New York, Rgenix Rises From Rockefeller and Takes Aim at Cancer",https://inspirna.com/in-new-york-rgenix-rises-from-rockefeller-and-takes-aim-at-cancer/,85,85,"Inspirna, Inc. is a privately-held clinical-stage biopharmaceutical. company focused on the discovery and development of novel cancer drugs. The company's drugs target key pathways in cancers of high unmet need. Inspirna is based in Long Island City, New York."
86,Inspirna,2024-01-04,Inspirna to Present at the 42nd Annual J.P. Morgan Healthcare Conference,https://inspirna.com/inspirna-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference/,86,86,"Inspirna, Inc. is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs. Inspirna’s lead drug candidate, ompenaclid (RGX-202), is an orally-administered small molecule that targets the CKB/SLC6A8 pathway."
87,Inspirna,2024-01-04,"Inspirna Partners with Merck KGaA, Darmstadt, Germany, to Accelerate Global Development of Ompenaclid (RGX-202)",https://inspirna.com/inspirna-partners-with-merck-kgaa-darmstadt-germany-to-accelerate-global-development-of-ompenaclid-rgx-202/,87,87,Ompenaclid (RGX-202) is a first-in-class oral inhibitor of the creatine transport channel SLC6A8. It is currently in development for RAS mutated (RASm) second-line (2L) advanced or metastatic colorectal cancer (mCRC) Inspirna will receive an upfront payment of $45 million.
88,Inspirna,2023-10-23,Inspirna Announces Clinical Data from Phase 1b/2 Study of Ompenaclid (RGX-202) in Advanced Colorectal Cancer at ESMO Congress 2023,https://inspirna.com/inspirna-announces-clinical-data-from-phase-1b-2-study-of-ompenaclid-rgx-202-in-advanced-colorectal-cancer-at-esmo-congress-2023/,88,88,"Ompenaclid (RGX-202) in combination with FOLFIRI and bevacizumab (BEV) in RAS-mutated (RASm) advanced or metastatic colorectal cancer (CRC) presented at the European Society for Medical Oncology (ESMO) Congress 2023 being held October 20-24, 2023 in Madrid, Spain. Inspirna hosted a virtual KOL panel on Sunday, October 22, to discuss these clinical data."
89,Inspirna,2023-10-16,Inspirna to Present Clinical Data from Phase 1b/2 Study of Ompenaclid (RGX-202) in Advanced Colorectal Cancer at ESMO Congress 2023,https://inspirna.com/inspirna-to-present-clinical-data-from-phase-1b-2-study-of-ompenaclid-rgx-202-in-advanced-colorectal-cancer-at-esmo-congress-2023/,89,89,"Inspirna, Inc. announced today that data from the ongoing Phase 1b/2 study of ompenaclid (RGX-202) in combination with FOLFIRI and bevacizumab (BEV) in RAS-mutated (RASm) advanced or metastatic colorectal cancer (CRC) will be presented at the European Society for Medical Oncology (ESMO) Congress 2023. Inspirna will host a virtual KOL panel to discuss the data on Sunday, October 22, 2023 at 12:30pm ET. A webcast of the event will be available on the “Events and Presentations"
90,Inspirna,2023-06-01,Inspirna to Present at the Jefferies Healthcare Conference,https://inspirna.com/inspirna-to-present-at-the-jefferies-healthcare-conference/,90,90,"Inspirna, Inc. is a clinical stage biopharmaceutical company developing first-in-class cancer therapeutics. Chief Executive Officer Dr. Usman “Oz” Azam, M.D., will participate in a corporate presentation at the Jefferies Healthcare Conference on June 8, 2023 at 1:30pm ET."
91,Inspirna,2023-05-01,"Inspirna Appoints Dr. Usman “Oz” Azam, M.D., as New Chief Executive Officer",https://inspirna.com/inspirna-appoints-dr-usman-oz-azam-m-d-as-new-chief-executive-officer/,91,91,"Inspirna appoints Dr. Usman “Oz” Azam, M.D., as its new Chief Executive Officer. Co-founder Masoud Tavazoie steps down as Chief Executive officer and Director. Dr. Azam brings over two decades of drug development experience."
92,Inspirna,2023-01-05,Inspirna Announces Interim Data from Phase 1b/2 Study of Abequolixron (RGX-104) in Relapsed or Refractory Lung Cancer,https://inspirna.com/inspirna-announces-interim-data-from-phase-1b-2-study-of-abequolixron-rgx-104-in-relapsed-or-refractory-lung-cancer/,92,92,"Abequolixron (RGX-104) is a first-in-class, small molecule liver X receptor (LXR) agonist designed to target APOE dysregulation and enhance anti-tumor immunity. The drug candidate could be a valuable addition to a current standard of care chemotherapy in heavily-pretreated patients with lung cancer."
93,Inspirna,2022-11-17,Inspirna to Present at the Evercore ISI Annual HealthCONx Conference,https://inspirna.com/inspirna-to-present-at-the-evercore-isi-annual-healthconx-conference/,93,93,"Inspirna, Inc. is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs. The company is pursuing several first-in-class drug candidates. Its lead drug candidate, RGX-202, is an orally-administered small molecule that targets the CKB/SLC6A8 pathway."
94,Inspirna,2022-07-11,Inspirna Raises $50 Million in Series D Financing,https://inspirna.com/inspirna-raises-50-million-in-series-d-financing/,94,94,"Inspirna, Inc. announced that it has raised $50 million in a Series D financing round. New investors Sands Capital and Vivo Capital, with additional participation from new investor Dreavent 6. Existing investors also participated in the financing round including Novo Holdings A/S, Sofinnova Partners, Sixty Degree Capital Fund."
95,Inspirna,2022-06-28,Inspirna to Present Phase 1b RGX-202-01 Clinical Trial Data at the 2022 ESMO World Congress on Gastrointestinal Cancer,https://inspirna.com/inspirna-to-present-phase-1b-rgx-202-01-clinical-trial-data-at-the-2022-esmo-world-congress-on-gastrointestinal-cancer/,95,95,"RGX-202-01 is an oral, potential first-in-class small molecule inhibitor of SLC6a8, a creatine transporter that drives colorectal cancer and certain other cancers’ progression. The drug is also very well-tolerated, enabling a safe and effective combination therapy with FOLFIRI/BEV to provide further optionality for patients."
96,Inspirna,2022-05-26,Inspirna to Present Phase 1b RGX-202-01 Clinical Trial Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting,https://inspirna.com/inspirna-to-present-phase-1b-rgx-202-01-clinical-trial-data-at-the-2022-american-society-of-clinical-oncology-asco-annual-meeting/,96,96,"RGX-202-01 is an oral, potential first-in-class small molecule inhibitor of SLC6a8, a creatine transporter that drives colorectal cancer and certain other cancers’ progression. It is currently being evaluated in a Phase 1b dose escalation and expansion study in combination with FOLFIRI/BEV. The primary endpoint of the study is to determine maximum tolerated dose (MTD), overall response rate (ORR), and treatment-emergent adverse events (TEAEs)"
97,Inspirna,2022-04-27,Inspirna Announces Phase 1b RGX-202 Clinical Trial Data Selected for Poster Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting,https://inspirna.com/inspirna-announces-phase-1b-rgx-202-clinical-trial-data-selected-for-poster-presentation-at-the-2022-american-society-of-clinical-oncology-asco-annual-meeting/,97,97,"Inspirna, Inc. will present a poster at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7 in Chicago, Illinois. Inspirna’s lead drug candidate RGX-202 is an orally-administered small molecule that targets the CKB/SLC6A8 pathway."
98,Inspirna,2022-04-07,Inspirna to Present at 21st Annual Needham Virtual Healthcare Conference,https://inspirna.com/inspirna-to-present-at-21st-annual-needham-virtual-healthcare-conference/,98,98,"Inspirna, Inc. is a privately-held clinical-stage biopharmaceutical company. The company is pursuing several first-in-class drug candidates to treat cancers of need. CEO Masoud Tavazoie will present at the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022."
99,Inspirna,2022-03-08,Inspirna to Participate in Multiple Virtual Healthcare Investor Conferences in March,https://inspirna.com/inspirna-to-participate-in-multiple-virtual-healthcare-investor-conferences-in-march/,99,99,"Inspirna, Inc. is a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics. CEO Masoud Tavazoie, M.D., Ph.D. will participate in multiple virtual healthcare investor conferences taking place during the month of March."
100,Inspirna,2021-12-09,Inspirna Strengthens Scientific Advisory Board with Two Globally Renowned Experts in Gastrointestinal Oncology,https://inspirna.com/inspirna-strengthens-scientific-advisory-board-with-two-globally-renowned-experts-in-gastrointestinal-oncology/,100,100,"Inspirna, Inc. announced today the appointment of Josep Tabernero, M.D., Ph.D. and Alan P. Venook, M,D., to its scientific advisory board. Dr. Taberneo is the Director of the Vall d’Hebron Institute of Oncology (VHIO) and Head of the Medical oncology Department of Vall d'Hebrons University Hospital. Dr Venook is the Madden Family Distinguished Professor of Medical Oncologist and Associate Director for Development at the University of California, San Francisco."
101,Inspirna,2021-11-22,Inspirna to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference,https://inspirna.com/inspirna-to-present-at-the-piper-sandler-33rd-annual-virtual-healthcare-conference/,101,101,"Inspirna, Inc. is a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics. CEO Masoud Tavazoie will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference at 10:00 A.M. EST on November 22, 2021."
102,Inspirna,2021-11-10,Inspirna to Present at the Stifel 2021 Virtual Healthcare Conference,https://inspirna.com/stifel-2021-virtual-healthcare-conference/,102,102,"Inspirna, Inc. will present at the Stifel 2021 Virtual Healthcare Conference at 10:40 A.M. EST on November 17, 2021. To view this virtual presentation, live, register for the event here. Inspirna identifies novel cancer targets using its RNA-based target discovery platform, RNA-DRIVErTM."
103,Inspirna,2021-11-04,Inspirna Announces Clinical Collaboration with Bristol Myers Squibb to Study RGX-104 in Combination with Yervoy® (ipilimumab) for Treatment of Metastatic Endometrial Cancer,https://inspirna.com/inspirna-announces-clinical-collaboration-with-bristol-myers-squibb-to-study-rgx-104-in-combination-with-yervoy-ipilimumab-for-treatment-of-metastatic-endometrial-cancer/,103,103,"Inspirna, Inc. announced a collaboration with Bristol Myers Squibb on a clinical trial of a combination therapy using RGX-104 (abequolixron), the Company’s small molecule agonist of the Liver X Receptor/Apolipoprotein E (“LXR/APOE”) pathway, and Yervoy (ipilimumab) The study will focus on patients with metastatic endometrial cancer whose genomes possess the E2 or E4 APOE genetic biomarker."
104,Inspirna,2021-09-30,RGENIX Announces Company Name Change to Inspirna and Expands Board of Directors with Appointment of Pharma Veteran Dieter Weinand,https://inspirna.com/rgenix-announces-company-name-change-to-inspirna-and-expands-board-of-directors-with-appointment-of-pharma-veteran-dieter-weinand/,104,104,"Inspirna, Inc., a privately-held biopharmaceutical company, announced today its corporate name change from Rgenix to Inspirna. The company also announced the appointment of Dieter Weinand to its Board of Directors, where he will serve as Chairman. Mr. Weinand, formerly CEO of Bayer Pharma AG, brings over 30 years of experience across the pharmaceutical and biotechnology industries."
105,Inspirna,2020-11-23,RGENIX to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference,https://inspirna.com/rgenix-to-present-at-piper-sandler-32nd-annual-virtual-healthcare-conference/,105,105,"Rgenix, Inc. is a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics. CEO Masoud Tavazoie, M.D., will present at the 32nd Annual Piper Sandler Virtual Healthcare Conference."
106,Inspirna,2020-11-04,RGENIX to Present at 2020 Stifel Virtual Healthcare Conference,https://inspirna.com/rgenix-to-present-at-2020-stifel-virtual-healthcare-conference/,106,106,"RGENIX, Inc. is a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics. CEO Masoud Tavazoie, M.D., Ph.D. will present at the 2020 Stifel Virtual Healthcare Conference on November 16, 2020."
107,Inspirna,2020-09-02,RGENIX to Present at H.C. Wainwright 22nd Annual Global Investment Conference,https://inspirna.com/rgenix-to-present-at-h-c-wainwright-22nd-annual-global-investment-conference/,107,107,"Rgenix will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020. The company is pursuing several first-in-class drug candidates to treat cancers of high unmet need. RGENIX identifies novel cancer targets using a microRNA based target discovery platform."
108,Inspirna,2020-08-05,RGENIX to Present at Multiple Virtual Healthcare Investor Conferences in August,https://inspirna.com/rgenix-to-present-at-multiple-virtual-healthcare-investor-conferences-in-august/,108,108,"RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that it has been selected to present at multiple virtual healthcare investor conferences. These conferences include: LifeSci Partners Summer Symposium, Wedbush PacGrow Healthcare Conference, and Canaccord Genuity 40th Annual Growth Conference."
109,Inspirna,2020-06-22,RGENIX Presents Biomarker and Efficacy Results from Phase 1 Dose Escalation Cohorts of RGX-104 at the 2020 AACR Annual Meeting,https://inspirna.com/rgenix-presents-biomarker-and-efficacy-results-from-phase-1-dose-escalation-cohorts-of-rgx-104-at-the-2020-aacr-annual-meeting/,109,109,The abstract was accepted for the 2020 American Association for Cancer Research (AACR) Annual Meeting. The abstract results will be presented as a virtual poster presentation (#LB-133/7) in the Late-Breaking Research: Clinical Research 1 session. RGX-104 is a small-molecule LXR agonist that modulates innate immunity via transcriptional activation of the ApoE gene.
110,Inspirna,2020-06-22,RGENIX Presents Results from Preclinical Safety and Efficacy Studies of RGX-019 at the 2020 AACR Annual Meeting,https://inspirna.com/rgenix-presents-results-from-preclinical-safety-and-efficacy-studies-of-rgx-019-at-the-2020-aacr-annual-meeting/,110,110,"RGENIX, Inc. is presenting an abstract on RGX-019, its pre-clinical antibody program in development. The abstract was accepted for the 2020 American Association for Cancer Research (AACR) Annual Meeting. The results will be presented as a virtual poster presentation (LB-090) during the Late-Breaking Research: Immunology 1 session."
111,Inspirna,2020-05-29,RGENIX Shows Clinical Activity of Novel Agent RGX-202 in Patients with KRAS Mutant Colorectal Cancer in Phase 1 Trial,https://inspirna.com/rgenix-shows-clinical-activity-of-novel-agent-rgx-202-in-patients-with-kras-mutant-colorectal-cancer-in-phase-1-trial/,111,111,RGX-202 is a first-in-class small molecule that inhibits a novel cancer metabolism pathway involved in supplying energy to cancer cells. The SLC6a8/CKB pathway was discovered using RGENIX’s proprietary miRNA-based target-discovery platform applied to KRAS mutant CRC.
112,Inspirna,2020-05-21,RGENIX To Present RGX-202 Phase I Data at 2020 ASCO Virtual Scientific Program,https://inspirna.com/rgenix-to-present-rgx-202-phase-i-data-at-2020-asco-virtual-scientific-program/,112,112,"Rgenix will present an oral abstract related to the RGX-202 program at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. The meeting is scheduled to take place May 29 – 31, 2020. RGENIX identifies novel cancer targets using a microRNA based target discovery platform. The company is pursuing several first-in-class drug candidates to treat cancers of high unmet need."
113,Inspirna,2020-04-27,RGENIX Presents Initial Results of Combination Trial of RGX-104 at the 2020 AACR Annual Meeting,https://inspirna.com/rgenix-presents-initial-results-of-combination-trial-of-rgx-104-at-the-2020-aacr-annual-meeting/,113,113,"RGX-104 is a small-molecule LXR agonist that modulates innate immunity via transcriptional activation of the ApoE gene. The safety profile was consistent with the individual profiles of RGx-104 and docetaxel, with neutropenia the most common drug-related adverse event observed. The results support further development of this regimen."
114,Inspirna,2020-02-26,Clinical Development of First-in-class Innate IO Agents,https://inspirna.com/clinical-development-of-first-in-class-innate-io-agents/,114,114,"The sixth IO360 conference in New York City gathers key representatives from industry, non-profits, regulatory bodies, investors and patients. Stakeholders will present and contrast strategies in IO from a scientific, clinical and regulatory viewpoint. Masoud Tavazoie, CEO of RGENIX, will present rationale and development strategies for novel modalities impacting the innate immune system."
115,Inspirna,2019-12-13,Rgenix Cancer Therapeutics Company Focuses on RNA to Identify Novel Targets,https://inspirna.com/rgenix-cancer-therapeutics-company-focuses-on-rna-to-identify-novel-targets/,115,115,"Inspirna, Inc. is a privately-held clinical-stage biopharmaceutical company. The company is focused on the discovery and development of novel cancer drugs that target key pathways in cancers of high unmet need. For confidential support call the Samaritans on 08457 90 90 90, visit a local Samaritans branch or see www.samaritans.org."
116,Inspirna,2019-10-16,Featured on In Vivo: “Rgenix: A Cancer Start-Up’s Resolve To Crack The Mystery Of Metastasis”,https://inspirna.com/featured-on-in-vivo-rgenix-a-cancer-start-ups-resolve-to-crack-the-mystery-of-metastasis/,116,116,"Rgenix, a New York-based start-up co-founded by three prominent physician researchers, is taking aim at what it contends is the future of cancer treatment. The company is focused on the discovery and development of novel cancer drugs that target key pathways in cancers of high unmet need."
117,Inspirna,2019-09-16,Rgenix Names Industry Veteran to Chief Medical Officer Role,https://inspirna.com/rgenix-names-industry-veteran-to-chief-medical-officer-role/,117,117,"Robert Wasserman, MD, joins Rgenix with more than 20 years of oncology clinical development experience and prior senior roles in the biopharma industry. Dr. Wasserman will oversee new Phase 1b/2 trial of lead compound RGX-104 in lung cancer patients."
118,Inspirna,2019-04-03,Rgenix Presents Pre-Clinical Data on RGX-019 at the  2019 AACR Annual Meeting,https://inspirna.com/rgenix-presents-pre-clinical-data-on-rgx-019-at-the-2019-aacr-annual-meeting/,118,118,Rgenix Presents Pre-Clinical Data on RGX-019 at the  2019 AACR Annual Meeting. Pre-clinical data demonstrates first-in-class MERTK selective inhibitor with novel mechanism of action. Rgenix has initiated IND-enabling studies of RGx-019.
119,Inspirna,2019-04-01,Rgenix To Present Abstract on RGX-019 at the 2019 AACR Annual Meeting,https://inspirna.com/rgenix-to-present-abstract-on-rgx-019-at-the-2019-aacr-annual-meeting/,119,119,"Rgenix, Inc. will present an abstract about Rgenix’s RGX-019 program at the 2019 American Association for Cancer Research Annual Meeting. The meeting is scheduled to take place Friday, March 29 through Wednesday, April 3 in Atlanta. Dr. Isabel Kurth, Ph.D., will present data from pre-clinical research of RGX -019."
120,Inspirna,2019-02-01,Translational and Clinical Development Strategies for IO Agents Targeting the Innate Immune System,https://inspirna.com/translational-and-clinical-development-strategies-for-io-agents-targeting-the-innate-immune-system/,120,120,Immuno-Oncology 360° brings together diverse stakeholders of drug development in immuno-oncology (IO) Dr. Tavazoie’s talk will highlight strategies to support the translation of preclinical data into the clinic specifically for modalities targeting the innate immune system.
121,Inspirna,2018-12-14,Xconomy: New York Biotech – How to make it here,https://inspirna.com/new-york-biotech-how-to-make-it-here/,121,121,"Rgenix, Inc. is a privately-held clinical-stage biopharmaceutical company. The company is focused on the discovery and development of novel cancer drugs. Rgenix has $40M in Series C funding and is based in Long Island City, New York."
122,Inspirna,2018-11-30,Rgenix CEO Masoud Tavazoie Discusses Immune System Regulation in Cancer at Plenary Session during AACR Meeting,https://inspirna.com/rgenix-ceo-masoud-tavazoie-discusses-immune-system-regulation-in-cancer-at-plenary-session-during-aacr-meeting/,122,122,Rgenix CEO Masoud Tavazoie Discusses Immune System Regulation in Cancer at Plenary Session during AACR Meeting. The LXR/ApoE pathway was discovered as a cancer pathway by Rgenix founding scientists utilizing an unbiased experimental approach to identify key drivers of cancer progression.
123,Inspirna,2018-11-27,Rgenix Appoints Serial Entrepreneur and Senior Executive Peter Van Vlasselaer to Board of Directors,https://inspirna.com/rgenix-appoints-serial-entrepreneur-and-senior-executive-peter-van-vlasselaer-to-board-of-directors/,123,123,"Peter Van Vlasselaer, Ph.D., is a serial entrepreneur and most recently the President and CEO of ARMO Biosciences, which he also founded. Rgenix identifies novel cancer targets using a microRNA-based target discovery platform. The company is pursuing several first-in-class drug candidates for cancers of high unmet need."
124,Inspirna,2018-11-27,AACR Tumor Immunology and Immunotherapy Conference,https://inspirna.com/aacr-tumor-immunology-and-immunotherapy-conference/,124,124,"Inspirna, Inc. is a privately-held clinical-stage biopharmaceutical. company focused on the discovery and development of novel cancer drugs. Inspirna's drugs target key pathways in cancers of high unmet need. The company is based in Long Island City, New York."
125,Inspirna,2018-10-31,Rgenix Treats First Patient in Phase 1 Trial of RGX-202,https://inspirna.com/rgenix-treats-first-patient-in-phase-1-trial-of-rgx-202/,125,125,"Rgenix, Inc. has treated the first patient in a Phase 1 a/b study of RGX-202, an oral small molecule being developed for the treatment of gastrointestinal cancers. Rgenix identifies novel cancer targets using a microRNA-based target discovery platform. The company is funded by leading biotechnology investors."
126,Inspirna,2018-10-09,Rgenix Raises $40M in Series C Funding To Support Clinical Stage Oncology Programs,https://inspirna.com/rgenix-raises-40m-in-series-c-funding-to-support-clinical-stage-oncology-programs/,126,126,"Rgenix, Inc. announced that it has raised $40 million in a Series C financing in support of further development of the company’s clinical and pre-clinical oncology programs. The financing will support Phase 1b/2 clinical trials of the lead program RGX-104 in multiple cancer indications, including in checkpoint inhibitor refractory patients. The company is pursuing several first-in-class drug candidates to treat cancers of high unmet need."
127,Inspirna,2018-06-04,Rgenix Presents Data on Phase I Clinical Activity For RGX-104 at the 2018 ASCO Annual Meeting,https://inspirna.com/rgenix-presents-data-on-phase-i-clinical-activity-for-rgx-104-at-the-2018-asco-annual-meeting/,127,127,"Rgenix is presenting data on the safety, pharmacodynamics, and clinical activity from the dose escalation stage of the ongoing Phase Ia/b trial of RGX-104. The small molecule depletes myeloid derived suppressor cells (MDSCs) and stimulates dendritic cells (DCs), activating anti-tumor immunity."
128,Inspirna,2018-05-31,Rgenix To Present Data on RGX-104 Clinical Activity at  2018 ASCO Annual Meeting,https://inspirna.com/rgenix-to-present-data-on-rgx-104-clinical-activity-at-2018-asco-annual-meeting/,128,128,Rgenix will present its abstract on RGX-104’s pharmacodynamic and clinical activity at the 2018 Annual Meeting of the American Society of Clinical Oncology. The meeting will take place in Chicago from June 1 through June 5. Rgenix identifies novel cancer targets using a microRNA based target discovery platform.
129,Inspirna,2018-05-25,"Pharmacodynamic and clinical activity of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies",https://inspirna.com/pharmacodynamic-and-clinical-activity-of-rgx-104/,129,129,"RGX-104 is a small-molecule LXR agonist that modulates innate immunity via transcriptional activation of the ApoE gene. To read the abstract, please click here.Inspirna, Inc. is a privately-held clinical-stage biopharmaceutical company."
130,Inspirna,2018-01-11,Rgenix Announces Publication In Cell Demonstrating Activation of LXR/ApoE with RGX-104 Enhances Antitumor Immunity,https://inspirna.com/rgenix-announces-publication/,130,130,"Rgenix, Inc. announced today the publication of clinical and pre-clinical results by research collaborators at Rgenix and The Rockefeller University. The results of the collaboration, published in the January 11 online issue of Cell, reveal that the Liver-X Receptor/Apolipoprotein E (LXR/ApoE) pathway regulates anti-tumor immunity."
131,Inspirna,2017-11-17,Liver X Factor,https://inspirna.com/liver-x-factor/,131,131,"Rgenix’s Liver X Agonist Could Help Overcome Checkpoint Resistance in Cancer. Rgenix is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs. To read the full article, please click here."
132,Inspirna,2017-11-17,Rgenix Reports Phase I Data for Cancer Compound RGX-104,https://inspirna.com/rgenix-reports-phase-i-data-for-cancer-compound-rgx-104-2/,132,132,"Rgenix Inc. (New York, N.Y.) reported preliminary data from a Phase Ia/Ib trial showing that oral RGX-104 led to 4 cases of stable disease among 12 evaluable patients with advanced solid malignancies and lymphoma. To read the full article, please click here."
133,Inspirna,2017-10-30,Rgenix Reports Preliminary Phase 1a/b Clinical Data Demonstrating Immune-stimulatory Activity with RGX-104 in Advanced Cancer Patients,https://inspirna.com/rgenix-reports-preliminary-phase-1a-b-clinical-data-2/,133,133,Preliminary Phase 1a/b data demonstrate RGX-104 modulates the innate immune system to stimulate T cell activation in a diverse group of heavily pre-treated patients. The company presented the data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia.
134,Inspirna,2017-10-29,Rgenix Reports Preliminary Phase 1a/b,https://inspirna.com/rgenix-reports-preliminary-phase-1a-b/,134,134,Preliminary Phase 1a/b data demonstrate RGX-104 modulates the innate immune system to stimulate T cell activation in a diverse group of heavily pre-treated patients with refractory solid cancers. The company presented the data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia.
135,Inspirna,2017-10-26,Rgenix to Present Early Clinical Data on RGX-104 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics,https://inspirna.com/rgenix-to-present-early-clinical-data-on-rgx-104/,135,135,"Rgenix, Inc. is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs. The company is pursuing several first-in-class drug candidates to treat cancers of high unmet need. Dr. Monica Mita, Principal Investigator of the RGX-104-001 study, will present at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics."
136,Inspirna,2017-10-09,Meet the 30 biotech leaders under 40 who are searching for breakthrough treatments and shaping the future of medicine,https://inspirna.com/meet-the-30-biotech-leaders-under-40/,136,136,"Meet the 30 biotech leaders under 40 who are searching for breakthrough treatments and shaping the future of medicine. To read the full piece, please click here. Visit inspirna.com for more information about Inspirna, a privately-held clinical-stage biopharmaceutical company."
137,Inspirna,2017-09-14,"For Rgenix CEO Masoud Tavazoie, fighting cancer is a family business",https://inspirna.com/for-rgenix-ceo-masoud-tavazoie-fighting-cancer-is-a-family-business/,137,137,"Rgenix CEO Masoud Tavazoie was recently interviewed for an article in The Pharma Letter. To read the full piece, please click here. Rgenix is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs."
138,Inspirna,2017-04-28,Rgenix Appoints Chief Medical Officer,https://inspirna.com/rgenix-appoints-chief-medical-officer/,138,138,"Rgenix, Inc. announced today the appointment of Roger Waltzman, M.D., M.B.A. as its Chief Medical Officer. Dr. Waltzman brings more than 20 years of experience in oncology across the entire new drug development and approval process. He will oversee clinical development, including clinical trial design and the new drug application process with regulators."
139,Inspirna,2017-01-06,"Rgenix Announces Treatment of First Patient in Phase 1 Trial of RGX-104, its Lead Immuno-Oncology Therapeutic",https://inspirna.com/rgenix-announces-treatment-of-first-patient-in-phase-1-trial-of-rgx-104/,139,139,Rgenix announces treatment of the first patient with its lead candidate RGX-104 in a Phase 1a/b study. The 80-patient study consists of an initial dose-escalation stage involving patients with advanced solid malignancies and lymphoma. The LXR-ApoE pathway was originally identified as a cancer target using a novel microRNA-based discovery platform.
140,Inspirna,2016-06-29,What does it take to succeed as a New York biotech startup?,https://inspirna.com/rgenix-announces-33-million-series-b-financing-to-develop-first-in-class-cancer-therapeutics/,140,140,"Inspirna, Inc. is a privately-held clinical-stage biopharmaceutical. company focused on the discovery and development of novel cancer drugs. The company is based in Long Island City, New York City. Inspirna is developing drugs that target key pathways in cancers of high unmet need."
141,Inspirna,2016-06-15,"Rgenix Raises $33M, Preps Cancer Trial For Drug Shelved By GSK",https://inspirna.com/rgenix-raises-33m-preps-cancer-trial-for-drug-shelved-by-gsk/,141,141,"Inspirna, Inc. is a privately-held clinical-stage biopharmaceutical. company focused on the discovery and development of novel cancer drugs. The company's drugs target key pathways in cancers of high unmet need. Inspirna is based in Long Island City, New York."
142,Inspirna,2016-06-15,"Rottweiler tested, Novo and Sofinnova back $33M round for Rgenix",https://inspirna.com/rottweiler-tested-novo-and-sofinnova-back-33m-round-for-rgenix/,142,142,"Inspirna, Inc. is a privately-held clinical-stage biopharmaceutical company. The company is focused on the discovery and development of novel cancer drugs that target key pathways in cancers of high unmet need. Rgenix is a publicly-held company."
143,Inspirna,2016-06-15,Rgenix Announces $33 Million Series B Financing to Develop First-in-Class Cancer Therapeutics,https://inspirna.com/rgenix-announces-33-million-series-b-financing-to-develop-first-in-class-cancer-therapeutics-2/,143,143,"Rgenix announced a $33 million Series B financing led by Novo A/S and Sofinnova Partners. The financing will support clinical development of Rgenix’s lead drug candidates, RGX-104 andRGX-202, as well as further development of its therapeutics pipeline."
144,Inspirna,2015-08-31,"In New York, Rgenix Rises From Rockefeller and Takes Aim at Cancer",https://inspirna.com/in-new-york-rgenix-rises-from-rockefeller-and-takes-aim-at-cancer/,144,144,"Inspirna, Inc. is a privately-held clinical-stage biopharmaceutical. company focused on the discovery and development of novel cancer drugs. The company's drugs target key pathways in cancers of high unmet need. Inspirna is based in Long Island City, New York."
145,MindMed,2024-03-11,MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference,https://ir.mindmed.co/news-events/press-releases/detail/139/mindmed-to-participate-in-the-leerink-partners-2024-global-biopharma-conference,145,145,"MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. The company will host one on one investor meetings at the Leerink Partners 2024 Global Biopharma Conference, which will be held in Miami, FL from March 11-13, 2024."
146,MindMed,2024-03-07,Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement,https://ir.mindmed.co/news-events/press-releases/detail/138/mind-medicine-mindmed-inc-announces-pricing-of-underwritten-offering-of-common-shares-and-concurrent-private-placement,146,146,"Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) announced the pricing of an underwritten offering of 16,666,667 common shares, no par value per share, at an offering price of $6.00 per common share. The Company has entered into share purchase agreements for a concurrent private placement of 12,500,000 common shares. Gross proceeds to MindMed, before deducting underwriting commissions, placement agent fees and other offering-related expenses, are expected to be approximately $175 million."
147,MindMed,2024-03-07,MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder,https://ir.mindmed.co/news-events/press-releases/detail/137/mindmed-receives-fda-breakthrough-therapy-designation-and-announces-positive-12-week-durability-data-from-phase-2b-study-of-mm120-for-generalized-anxiety-disorder,147,147,MindMed announces FDA has granted breakthrough designation to its MM120 (lysergide d-tartrate) program for the treatment of generalized anxiety disorder (GAD) The Company also announced that its Phase 2b study of MM120 in GAD met its key secondary endpoint.
148,Molecular Templates,2024-03-04,"Molecular Templates, Inc. Provides Interim Update",https://www.mtem.com/investors/news-events-DQFwMCk3/press-releases-Ke9B82cd/detail/135/molecular-templates-inc-provides-interim-update,148,148,"Morale, ethics and culture of the board of directors of a company are key factors in a company's decision-making process. A company's management team is responsible for setting the tone and tone of its operations. The board of Directors has the power to appoint or remove members of its management team. The company has the responsibility to set the tone, tone and style of the company."
149,Molecular Templates,2024-02-08,Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference,https://www.mtem.com/investors/news-events-DQFwMCk3/press-releases-Ke9B82cd/detail/134/molecular-templates-to-present-at-oppenheimer-34th-annual,149,149,"Morale, ethics and culture of the board of directors of a company are key factors in a company's decision-making process. A company's management team is responsible for setting the tone and tone of its operations. The board of Directors has the power to appoint or remove members of its management team. The company has the responsibility to set the tone, tone and style of the company."
150,Molecular Templates,2023-11-13,"Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update",https://www.mtem.com/investors/news-events-DQFwMCk3/press-releases-Ke9B82cd/detail/133/molecular-templates-inc-reports-third-quarter-2023,150,150,"Morale, ethics and culture of the board of directors of a company are key factors in a company's decision-making process. A company's management team is responsible for setting the tone and tone of its operations. The board of Directors has the power to appoint or remove members of its management team. The company has the responsibility to set the tone, tone and style of the company."
151,Ribon Therapeutics,2023-03-09,Ribon Therapeutics Doses First Patient in Phase 1 Clinical Study with RBN-3143 in Patients with Moderate-to-Severe Atopic Dermatitis,https://ribontx.com/ribon-therapeutics-doses-first-patient-in-phase-1-clinical-study-with-rbn-3143-in-patients-with-moderate-to-severe-atopic-dermatitis/,151,151,"Ribon Therapeutics doses first patient in Phase 1 Clinical Study with RBN-3143 in Patients with Moderate-to-Severe Atopic Dermatitis. First-in-class, oral, small molecule inhibitor of PARP14 has the potential to treat a range of inflammatory diseases."
152,Ribon Therapeutics,2023-01-30,Ribon Therapeutics Announces $25 Million Equity Investment from Pfizer,https://ribontx.com/ribon-therapeutics-announces-25-million-equity-investment-from-pfizer/,152,152,"Ribon Therapeutics announced a $25 million investment from Pfizer. Ribon plans to use the proceeds to support clinical development of its potentially first-in-class oral small molecule programs in oncology and immunology. As part of the investment, Robert Rickert, Ph.D., will join Ribon’s Scientific Advisory Board."
153,Ribon Therapeutics,2022-11-29,Ribon Therapeutics Announces Acquisition of Pre-Clinical CD38 Program by Boehringer Ingelheim,https://ribontx.com/ribon-therapeutics-announces-acquisition-of-pre-clinical-cd38-program-by-boehringer-ingelheim/,153,153,"Boehringer Ingelheim aims to develop novel therapies based on Ribon’s CD38 program to transform the lives of patients with immunological and fibrotic diseases. Under the terms of the agreement, Ribon will receive an undisclosed upfront payment and is eligible to receive future payments related to preclinical, clinical, regulatory and commercial milestones."
154,Ribon Therapeutics,2022-09-06,Ribon Therapeutics Announces Late-Breaking Presentation of Preclinical Data on RBN-3143 at the European Respiratory Society International Congress 2022,https://ribontx.com/ribon-therapeutics-announces-late-breaking-presentation-of-preclinical-data-on-rbn-3143-at-the-european-respiratory-society-international-congress-2022/,154,154,"RBN-3143 is a novel, orally administered, first-in-class inhibitor of PARP14 with potential in a range of inflammatory diseases. The data were presented in a late-breaking poster at the European Respiratory Society (ERS) International Congress 2022."
155,Ribon Therapeutics,2022-04-11,Ribon Therapeutics Announces Presentations at the American Association for Cancer Research 2022 Annual Meeting,https://ribontx.com/ribon-therapeutics-announces-presentations-at-the-american-association-for-cancer-research-2022-annual-meeting/,155,155,"RBN-2397 is a small molecule inhibitor of PARP7 being evaluated in multiple clinical trials for the treatment of cancer. The oral presentation and poster presentation was presented today, April 11, 2022, at the American Association for Cancer Research (AACR) Annual Meeting 2022."
156,Ribon Therapeutics,2022-03-29,Ribon Therapeutics Announces Initiation of Phase 1b/2 Study of RBN-2397 in Combination with Pembrolizumab in Patients with Squamous Cell Carcinoma of the Lung,https://ribontx.com/ribon-therapeutics-announces-initiation-of-phase-1b-2-study-of-rbn-2397-in-combination-with-pembrolizumab-in-patients-with-squamous-cell-carcinoma-of-the-lung/,156,156,Ribon Therapeutics announces first patient dosed in Phase 1b/2 study of RBN-2397 in combination with pembrolizumab in patients with squamous cell carcinoma of the lung (SCCL) The first-in-class oral PARP7 inhibitor is expected to improve outcomes of patients treated with immune checkpoint inhibitors.
157,Ribon Therapeutics,2022-03-22,Ribon Therapeutics Initiates First-in-Human Phase 1 Clinical Study of RBN-3143 for the Treatment of Atopic Dermatitis,https://ribontx.com/ribon-therapeutics-initiates-first-in-human-phase-1-clinical-study-of-rbn-3143-for-the-treatment-of-atopic-dermatitis/,157,157,"RBN-3143 is a novel, orally administered, first-in-class inhibitor of PARP14 with potential as a therapy in a range of inflammatory diseases, with an initial focus in atopic dermatitis. In preclinical inflammatory disease models, we observed that oral dosing with RBN- 3143 led to a decrease of key inflammatory cytokines and cells such as eosinophils and neutrophils."
158,Ribon Therapeutics,2022-02-17,"Ribon Therapeutics, a Clinical Stage Biotechnology Company Targeting Stress Support Pathways in Cancer and Inflammation, Announces CEO Transition for Its Next Phase of Growth",https://ribontx.com/ribon-therapeutics-a-clinical-stage-biotechnology-company-targeting-stress-support-pathways-in-cancer-and-inflammation-announces-ceo-transition-for-its-next-phase-of-growth/,158,158,"Prakash Raman, Ph.D., appointed as President, Chief Executive Officer and member of the Board of Directors of Ribon Therapeutics. Dr. Raman succeeds Victoria Richon, who will remain as an R&D advisor to the Board and Chair of the Scientific Advisory Board. Ribon is a clinical stage biotechnology company developing therapeutics targeting stress support pathways."
159,Ribon Therapeutics,2021-09-27,Ribon Therapeutics Named a “Fierce 15” Biotech Company by Fierce Biotech,https://ribontx.com/ribon-therapeutics-named-a-fierce-15-biotech-company-by-fierce-biotech/,159,159,"Ribon Therapeutics has been named by Fierce Biotech as one of 2021’s Fierce 15 biotechnology companies. Ribon is developing first-in-class precision therapies targeting stress support pathways in cancer and inflammation for patients with limited options. The lead program is RBN-2397, a PARP7 inhibitor in clinical development for the treatment of cancer."
160,Ribon Therapeutics,2021-09-01,Ribon Therapeutics Announces Key Management Promotions,https://ribontx.com/ribon-therapeutics-announces-key-management-promotions/,160,160,"Ribon Therapeutics announces key management promotions. Heike Keilhack, Ph.D., is promoted to Chief Scientific Officer. Kevin Kuntz is appointed Chief Drug Development Officer. Ribon is a clinical stage biotechnology company developing therapeutics targeting stress support pathways."
161,Ribon Therapeutics,2021-07-22,Ribon Therapeutics Announces Publication in Cancer Cell of Pre-Clinical and Mechanism of Action Data for RBN-2397,https://ribontx.com/ribon-therapeutics-announces-publication-in-cancer-cell-of-pre-clinical-and-mechanism-of-action-data-for-rbn-2397/,161,161,"Ribon Therapeutics announced the first publication in the peer-reviewed journal, Cancer Cell, of preclinical data from its lead asset, RBN-2397. The published data demonstrate that inhibition of PARP7 can activate antitumor immune responses in cancer cells through restoration of Type I interferon (IFN) signaling."
162,Ribon Therapeutics,2021-07-14,Ribon Therapeutics Secures $65 Million Financing,https://ribontx.com/ribon-therapeutics-secures-65-million-financing/,162,162,"Ribon Therapeutics announced the closing of a $65 million financing. Ribon will use the proceeds to support the clinical development of its novel precision medicine candidates. The financing was led by Deerfield Management and U.S. Venture Partners, with support from new investors Avego BioScience Capital, GV (formerly Google Ventures), Monashee Investment Management and Peregrine Ventures."
163,Ribon Therapeutics,2021-06-28,Ribon Therapeutics Appoints Paul Brannelly as Chief Financial Officer,https://ribontx.com/ribon-therapeutics-appoints-paul-brannelly-as-chief-financial-officer/,163,163,"Paul Brannelly is a corporate finance veteran, having raised over $1.4 billion in debt and equity throughout his career. He most recently served as Executive Vice President, Chief Financial Officer of Collegium Pharmaceutical, Inc. He brings more than 20 years of senior public and private company development and financial management experience as an executive in the biopharma industry."
164,Ribon Therapeutics,2021-06-04,Ribon Therapeutics Announces Oral Presentation of Positive Interim Data from Phase 1 Trial of RBN-2397 in Patients with Advanced Solid Tumors at 2021 ASCO Annual Meeting,https://ribontx.com/ribon-therapeutics-announces-oral-presentation-of-positive-interim-data-from-phase-1-trial-of-rbn-2397-in-patients-with-advanced-solid-tumors-at-2021-asco-annual-meeting/,164,164,"Ribon Therapeutics announced positive interim clinical data from the dose escalation portion of its first-in-human Phase 1 trial evaluating RBN-2397. The data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 4, 2021."
165,Ribon Therapeutics,2021-05-20,Ribon Therapeutics Announces Oral Presentation of RBN-2397 Clinical Data at 2021 ASCO Annual Meeting,https://ribontx.com/ribon-therapeutics-announces-oral-presentation-of-rbn-2397-clinical-data-at-2021-asco-annual-meeting/,165,165,"Ribon Therapeutics is a clinical stage biotechnology company developing therapeutics targeting stress support pathways. RBN-2397, its small molecule inhibitor of PARP7, as a monotherapy in patients with advanced solid tumors was selected for an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting."
166,Ribon Therapeutics,2021-04-29,Ribon Therapeutics Announces Upcoming Presentation on RBN-2397 at the 2021 ASCO Annual Meeting,https://ribontx.com/ribon-therapeutics-announces-upcoming-presentation-on-rbn-2397-at-the-2021-asco-annual-meeting/,166,166,"Ribon Therapeutics announced oral presentation on RBN-2397 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 4 to 8, 2021. The full meeting program is available at: www.asco.org."
167,Ribon Therapeutics,2021-04-06,Ribon Therapeutics Announces Upcoming Presentations at the AACR 2021 Virtual Annual Meeting,https://ribontx.com/ribon-therapeutics-announces-upcoming-presentations-at-the-aacr-2021-virtual-annual-meeting/,167,167,"RBN-2397 is a PARP7 inhibitor that induces cancer cell autonomous and immune stimulatory effects in preclinical models. The company will present one oral and four poster presentations at the American Association for Cancer Research (AACR) 2021 Virtual Annual Meeting (Week 1), taking place from April 10 to 15, 2021."
168,Ribon Therapeutics,2021-02-02,"Ribon Therapeutics Announces License Agreement with Ono Pharmaceutical Co., Ltd. to Develop and Commercialize RBN-2397 In Japan, South Korea, Taiwan and ASEAN Countries",https://ribontx.com/ribon-therapeutics-announces-license-agreement-with-ono-pharmaceutical-co-ltd-to-develop-and-commercialize-rbn-2397-in-japan-south-korea-taiwan-and-asean-countries/,168,168,"Ribon Therapeutics Announces License Agreement with Ono Pharmaceutical Co., Ltd. to Develop and Commercialize RBN-2397 In Japan, South Korea, Taiwan and ASEAN Countries. Ono to make upfront payment of approximately $16.3 million to Ribon in addition to other potential milestone payments of approximately$132 million."
169,Ribon Therapeutics,2020-11-16,Ribon Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference,https://ribontx.com/ribon-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference/,169,169,"Ribon Therapeutics is a clinical stage oncology company developing first-in-class therapeutics targeting stress response pathways. Victoria Richon, Ph.D., President and Chief Executive Officer, will present a corporate overview at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held November 30 – December 3, 2020."
170,Ribon Therapeutics,2020-11-09,Ribon Therapeutics Announces the Appointment of Emma Reeve to the Company’s Board of Directors,https://ribontx.com/ribon-therapeutics-announces-the-appointment-of-emma-reeve-to-the-companys-board-of-directors/,170,170,"Ribon Therapeutics announced the appointment of Emma Reeve to its Board of Directors. Reeve is a distinguished industry veteran who brings over 20 years of global financial experience across pharmaceutical, medical device and bio-pharma companies. She currently serves as Chief Financial Officer at Constellation Pharmaceuticals."
171,Ribon Therapeutics,2020-07-16,Ribon Therapeutics Announces Appointment of Jodie P. Morrison as Chair of the Company’s Board of Directors,https://ribontx.com/ribon-therapeutics-announces-appointment-of-jodie-p-morrison-as-chair-of-the-companys-board-of-directors/,171,171,"Ribon Therapeutics is a clinical-stage oncology company developing first-in-class therapeutics targeting stress response pathways. Jodie P. Morrison has assumed the chair role of its board of directors, effective July 15, 2020. Morrison brings more than 20 years of executive leadership and therapeutics development expertise within the biopharmaceutical industry."
172,Ribon Therapeutics,2020-06-22,Ribon Therapeutics Presents Additional Preclinical Data on its PARP7 Inhibitor – RBN-2397 – and Demonstrates Broad Potential of its Platform at the AACR 2020 Virtual Meeting II,https://ribontx.com/ribon-therapeutics-presents-additional-preclinical-data-on-its-parp7-inhibitor-rbn-2397-and-demonstrates-broad-potential-of-its-platform-at-the-aacr-2020-virtual-meeting-ii/,172,172,"Ribon Therapeutics, a clinical stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced new data to be presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II, taking place from June 22-24, 2020. The posters presented at AACR provide a glimpse into Ribon’s unique ability to interrogate the complex biology of stress support pathways to identify novel therapeutic targets."
173,Ribon Therapeutics,2020-05-26,Ribon Therapeutics to Present at the Jefferies Virtual Healthcare Conference,https://ribontx.com/ribon-therapeutics-to-present-at-the-jefferies-virtual-healthcare-conference/,173,173,"Ribon Therapeutics is a clinical stage oncology company developing first-in-class therapeutics targeting stress response pathways. CEO Victoria Richon will provide a corporate overview and an update on the company’s lead clinical program, PARP7 inhibitor RBN-2397, at the Jefferies 2020 Virtual Healthcare Conference."
174,Ribon Therapeutics,2020-05-15,Ribon Therapeutics to Present New Preclinical Data on its PARP7 Inhibitor – RBN-2397 – and its Discovery Platform at the Upcoming AACR 2020 Virtual Meeting II,https://ribontx.com/ribon-therapeutics-to-present-new-preclinical-data-on-its-parp7-inhibitor-rbn-2397-and-its-discovery-platform-at-the-upcoming-aacr-2020-virtual-meeting-ii/,174,174,"Ribon Therapeutics to present new data at the upcoming American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II, taking place from June 22-24, 2020. The company's lead program is RBN-2397, a first-in-class PARP7 inhibitor in development for the treatment of cancer."
175,Ribon Therapeutics,2020-05-04,Ribon Therapeutics to Present at Upcoming Healthcare Conferences,https://ribontx.com/ribon-therapeutics-to-present-at-upcoming-healthcare-conferences/,175,175,"Ribon Therapeutics is a clinical-stage oncology company developing first-in-class therapeutics targeting stress response pathways. Victoria Richon, Ph.D., President and CEO, will present at two upcoming virtual healthcare conferences. Presentations will consist of a panel discussion and a corporate overview."
176,Ribon Therapeutics,2020-04-27,Ribon Therapeutics Presents Preclinical Data from its PARP7 and PARP14 Programs at AACR Virtual Meeting I,https://ribontx.com/ribon-therapeutics-presents-preclinical-data-from-its-parp7-and-parp14-programs-at-aacr-virtual-meeting-i/,176,176,"Ribon Therapeutics is a clinical-stage oncology company developing first-in-class therapeutics targeting stress response pathways. Lead program, PARP7 inhibitor RBN-2397, demonstrates complete tumor regression in preclinical cancer models. In vitro data illustrate the immune-suppressive role PARP14 plays in the tumor microenvironment."
177,Ribon Therapeutics,2020-04-14,Ribon Therapeutics to Present New Preclinical Data at the Upcoming AACR Virtual Annual Meetings,https://ribontx.com/ribon-therapeutics-to-present-new-preclinical-data-at-the-upcoming-aacr-virtual-annual-meetings/,177,177,"Ribon Therapeutics to present new data at the upcoming American Association for Cancer Research (AACR) Virtual Annual Meeting I, taking place from April 27-28, 2020. This meeting will feature a selection of high-impact proffered paper presentations, including: Advances in Cancer Drug Design and Discovery."
178,Ribon Therapeutics,2020-01-24,Ribon Therapeutics to Present at Upcoming Scientific Conferences,https://ribontx.com/ribon-therapeutics-to-present-at-upcoming-scientific-conferences/,178,178,"Ribon Therapeutics is a biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions. The company will be presenting at two upcoming scientific conferences. Ribon's lead program is RBN-2397, a first- in-class PARP7 inhibitor in development for the treatment of cancer."
179,Ribon Therapeutics,2020-01-06,Ribon Therapeutics Named as a Top Life Sciences Company to Watch in 2020,https://www.biospace.com/article/top-21-life-science-startups-to-watch-in-2020/,179,179,"The NextGen Bio Class of 2020 is a stellar group of companies that are already making an enormous impact on the industry now and will continue into the future. To come up with this list, BioSpace sorted companies into that age grouping, and they were then weighted by a number of different categories and finally ranked in a cumulative fashion, based on the points awarded for each category."
180,Ribon Therapeutics,2019-12-18,"Ribon Therapeutics Strengthens Scientific Advisory Board with Appointment of Neal Rosen, M.D., Ph.D.",https://ribontx.com/ribon-therapeutics-strengthens-scientific-advisory-board-with-appointment-of-neal-rosen-m-d-ph-d/,180,180,"Ribon Therapeutics announces the appointment of Neal Rosen, M.D., Ph.D. to its scientific advisory board (SAB) Dr. Rosen is a Member of the Molecular Pharmacology Program and the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK) He is the incumbent of the Enid A. Haupt Chair in Medical Oncology at MSK."
181,Ribon Therapeutics,2019-09-04,"Ribon Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of RBN-2397, a First-In-Class PARP7 Inhibitor",https://ribontx.com/ribon-therapeutics-announces-dosing-of-first-patient-in-phase-1-clinical-trial-of-rbn-2397-a-first-in-class-parp7-inhibitor/,181,181,"Ribon Therapeutics announced the dosing of the first patient in its Phase 1 clinical trial of RBN-2397, the company’s first-in-class PARP7 inhibitor. The Phase 1 trial is the first-ever clinical evaluation of a monoPARP inhibitor."
182,Ribon Therapeutics,2019-08-06,"Ribon Therapeutics Strengthens Management Team with Appointment of Sudha Parasuraman, M.D., as Chief Medical Officer and Edward Stewart as Chief Business Officer",https://ribontx.com/ribon-therapeutics-strengthens-management-team-with-appointment-of-sudha-parasuraman-m-d-as-chief-medical-officer-and-edward-stewart-as-chief-business-officer/,182,182,"Ribon Therapeutics announces the appointments of Sudha Parasuraman, M.D., and Edward “Tad” Stewart to the newly created positions of Chief Medical Officer (CMO) and Chief Business Officer, respectively. Dr. Parasuaman is a board-certified hematologist-oncologist with more than 20 years in the healthcare industry and broad experience across the spectrum of oncology drug development. Mr. Stewart brings more than20 years of executive experience in the biotechnology area with a focus on business development, strategy and commercialization."
183,Ribon Therapeutics,2019-01-04,Ribon Therapeutics Raises $65 Million to Advance Pipeline of Novel Therapeutics Targeting Cellular Stress Pathways for Cancer,https://ribontx.com/ribon-press-release/,183,183,"Ribon Therapeutics announces the closing of a $65 million Series B financing. Proceeds will be used to advance lead programs from the company’s growing pipeline into clinical testing. The financing was led by the Novartis Venture Fund, with participation from new investors JJDC and Celgene Corporation."
184,Tscan Therapeutics,2024-03-06,TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update,https://ir.tscan.com/news-releases/news-release-details/tscan-therapeutics-reports-fourth-quarter-and-full-year-2023,184,184,"TScan Therapeutics, Inc. (Nasdaq: TCRX) is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies. The company recently announced the clearance of two additional INDs for Solid Tumor Program: TSC-201-B0702 targeting MAGE-C2 on HLA-B*07:02."
185,Tscan Therapeutics,2024-02-28,TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference,https://ir.tscan.com/news-releases/news-release-details/tscan-therapeutics-participate-td-cowen-44th-annual-health-care,185,185,"TScan Therapeutics, Inc. (Nasdaq: TCRX) will participate in the Cell Therapy Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference on March 6, 2024. A webcast of the panel discussion will be available on the “Events and Presentations” section of the Company’s website at irtscan.com."
186,Tscan Therapeutics,2024-02-26,TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR,https://ir.tscan.com/news-releases/news-release-details/tscan-therapeutics-presents-promising-updated-phase-1-clinical,186,186,"TScan Therapeutics, Inc. (Nasdaq: TCRX) is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies. Company to host virtual KOL event today, Monday, February 26, at 8:00 a.m. ET, to discuss the data presented at the 2024 Tandem Meetings."
187,VBI Vaccines,2024-02-14,"VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences",https://www.vbivaccines.com/press-releases/vbi-announces-agreement-to-sell-manufacturing-capabilities-certain-related-assets-and-enter-into-new-license-agreement-with-brii-biosciences/,187,187,"VBI Vaccines Inc. (Nasdaq: VBIV) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Brii Biosciences (“Brii Bio”), subject to certain activities, is expected to: (i) acquire the intellectual property for VBI-2601, VBI’s HBV immunotherapeutic development program, and eliminate payment obligations from the July 2023 agreements between VBI and Brii Bio. (ii) acquire manufacturing capabilities and certain related assets at VBI's Rehovot, Israel manufacturing facility, and (iii) enter into an exclusive license"
188,VBI Vaccines,2023-11-20,VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting,https://www.vbivaccines.com/press-releases/vbi-vaccines-presents-additional-biomarker-data-from-phase-1-2a-study-of-vbi-1901-in-recurrent-gbm-at-the-2023-society-for-neuro-oncology-sno-annual-meeting/,188,188,"VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that additional biomarker data from the Phase 1/2a study of VBI-1901, the Company’s cancer vaccine immunotherapeutic candidate, in recurrent glioblastoma (GBM) patients. Data showed there were higher blood/plasma levels of C4G in patients who achieved partial tumor responses than in patients with stable or progressive disease."
189,VBI Vaccines,2023-11-14,VBI Vaccines Reports Third Quarter 2023 Financial Results,https://www.vbivaccines.com/press-releases/vbi-vaccines-reports-third-quarter-2023-financial-results/,189,189,"VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended September 30, 2023."
190,VBI Vaccines,2023-10-26,VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program,https://www.vbivaccines.com/press-releases/vbi-vaccines-expands-proprietary-technology-platforms-with-development-of-a-novel-mrna-launched-evlp-vaccine-program/,190,190,"VBI Vaccines Inc. (Nasdaq: VBIV) announced the development of its next-generation mRNA-launched enveloped virus-like particle (eVLP) technology. MLE technology uses the human body as a bioreactor to produce complex proteins that mimic the natural viral targets, stimulating a strong functional immune response."
191,VBI Vaccines,2023-09-27,"VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern",https://www.vbivaccines.com/press-releases/vbi-vaccines-pan-coronavirus-vaccine-candidate-vbi-2901-induced-broad-and-durable-protective-titers-against-variants-of-concern/,191,191,"VBI Vaccines Inc. announced interim data from the Phase 1 clinical study of its multivalent pan-coronavirus vaccine candidate, VBI-2901. The vaccine expresses the ancestral COVID-19, SARS, and MERS spike antigens."
192,VBI Vaccines,2023-09-07,VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM,https://www.vbivaccines.com/press-releases/vbi-vaccines-announces-dosing-of-first-patients-in-phase-2b-study-of-vbi-1901-in-recurrent-gbm/,192,192,"First patients have been dosed in the randomized, controlled Phase 2b study of VBI’s cancer vaccine immunotherapeutic candidate, VBI-1901, in patients with first recurrent glioblastoma (rGBM) The study will assess the safety, tolerability, tumor response rates, and survival following treatment with VBI, as a monotherapy, at 10 leading neuro-oncology centers across the United States."
193,VBI Vaccines,2023-09-06,VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis B,https://www.vbivaccines.com/press-releases/vbi-vaccines-partner-brii-biosciences-announces-topline-interim-results-of-phase-2-study-evaluating-brii-179-vbi-2601-in-combination-with-peg-ifn-for-the-treatment-of-chronic-hepatitis-b/,193,193,"VBI Vaccines Inc. (Nasdaq: VBIV) announced that its strategic hepatitis B (HBV) partner, Brii Biosciences (Brii Bio) (Stock code: 2137.HK), announced topline cohort-level unblinded Week 36 data from interim analysis of a randomized, placebo-controlled and double-blinded Phase 2 study. BRII-179 (VBI-2601) is a first-in-class Pre-S1/Pre-S2/S therapeutic vaccine."
194,VBI Vaccines,2023-08-14,VBI Vaccines Reports Second Quarter 2023 Financial Results,https://www.vbivaccines.com/press-releases/vbi-vaccines-reports-second-quarter-2023-financial-results/,194,194,"VBI Vaccines Inc. (Nasdaq: VBIV) announced financial results for the quarter ended June 30, 2023. Global net revenue increased 48% quarter-over-quarter from Q1 to Q2 2023 – redefined, highly targeted commercial field team deployed at the end of Q2. Expanded hepatitis B collaboration with Brii Biosciences announced in July for $15 million upfront, including a $3 million equity investment."
195,VBI Vaccines,2023-07-24,VBI Vaccines Announces Closing of Underwriters’ Partial Exercise of Option to Purchase Additional Common Shares,https://www.vbivaccines.com/press-releases/vbi-vaccines-announces-closing-of-underwriters-partial-exercise-of-option-to-purchase-additional-common-shares/,195,195,"VBI Vaccines Inc. (NASDAQ: VBIV) announced that the underwriters of its recent underwritten public offering of common shares partially exercised their option to purchase an additional 1,536,363 common shares at a public offering price of $1.64 per common share. The aggregate gross proceeds from this exercise were approximately $2.5 million. The Company intends to use the net proceeds from the underwritten offering, including the partial option exercise, for the commercialization activities for PreHevbrio."
196,VBI Vaccines,2023-07-19,VBI Vaccines Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults,https://www.vbivaccines.com/press-releases/vbi-vaccines-announces-prehevbri-is-now-available-in-the-netherlands-and-belgium-for-the-prevention-of-hepatitis-b-in-adults/,196,196,"PreHevbri is the only 3-antigen hepatitis B vaccine, comprised of the three hepatitis B surface antigens of the hepatitis B virus. It is approved for use in the European Union/European Economic Area, United Kingdom, United States, Canada, and Israel. An estimated 900,000 people die each year from complications of chronic HBV."
197,VBI Vaccines,2023-07-06,VBI Vaccines Announces Pricing of $18 Million Public Offering and $3 Million Concurrent Registered Direct Offering,https://www.vbivaccines.com/press-releases/vbi-vaccines-announces-pricing-of-18-million-public-offering-and-3-million-concurrent-registered-direct-offering/,197,197,"VBI Vaccines Inc. (NASDAQ: VBIV) (VBI or the Company) announced the pricing of its previously announced underwritten public offering of 10,909,091 common shares and accompanying common warrants. VBI also granted the underwriters a 30-day option to purchase up to an additional 1,636,363 common shares. The gross proceeds from the concurrent registered direct offering are expected to be approximately $3 million."
198,VBI Vaccines,2023-07-05,VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares and Warrants,https://www.vbivaccines.com/press-releases/proposed-concurrent-public-offering-and-registered-direct-offering-of-common-shares-and-warrants-june-2023/,198,198,"VBI Vaccines Inc. (NASDAQ: VBIV) has commenced an underwritten public offering and a registered direct offering of its common shares and accompanying common warrants. VBI intends to use the net proceeds from both offerings for the commercialization activities for PreHevbrio [Hepatitis B Vaccine (Recombinant)] in the United States, Europe, and Canada."
199,VBI Vaccines,2023-07-05,VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus Royalties,https://www.vbivaccines.com/press-releases/vbi-vaccines-and-brii-biosciences-expand-hepatitis-b-partnership-to-address-both-prevention-and-treatment-in-license-and-collaboration-agreements-for-up-to-437-million-plus-royalties/,199,199,"VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI” or the “Company”) announced the expansion of its hepatitis B (HBV) partnership with Brii Biosciences. Through two license and collaboration agreements, Brii Bio expanded its exclusive license to VBI-2601 (BRII-179), VBI’s HBV immunotherapeutic candidate, to global rights and acquired an exclusive license for PreHevbri in the Asia Pacific region (APAC)"
200,VBI Vaccines,2023-06-23,VBI Vaccines Announces Results of Annual General Meeting,https://www.vbivaccines.com/press-releases/vbi-vaccines-announces-results-of-annual-general-meeting-2023/,200,200,"VBI Vaccines Inc. (Nasdaq: VBIV) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system."
201,VBI Vaccines,2023-06-15,VBI Vaccines Announces PreHevbri® is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults,https://www.vbivaccines.com/press-releases/vbi-vaccines-announces-prehevbri-is-now-available-in-the-united-kingdom-for-the-prevention-of-hepatitis-b-in-adults/,201,201,"PreHevbri is the only approved 3-antigen hepatitis B vaccine for adults in the U.K. It is approved for use in the European Union/European Economic Area, United States, Canada, and Israel. Hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection."
202,VBI Vaccines,2023-06-07,VBI Vaccines Announces Poster Presentation at EASL 2023,https://www.vbivaccines.com/press-releases/easl-2023/,202,202,"An abstract highlighting T-cell responses and durability of immune responses following vaccination with VBI’s 3-antigen hepatitis B (HBV) vaccine, PreHevbrio™ [Hepatitis B Vaccine (Recombinant)], has been accepted for poster presentation at The International Liver Congress™ 2023."
203,VBI Vaccines,2023-05-15,VBI Vaccines Reports First Quarter 2023 Financial Results,https://www.vbivaccines.com/press-releases/vbi-vaccines-reports-first-quarter-2023-financial-results/,203,203,"VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended March 31, 2023. PreHevbrio (Hepatitis B Vaccine [Recombinant] global net revenue increased 90% quarter-over-quarter from Q4 2022 to Q1 2023 as access to PreHeVbrio continues to broaden. Initial Phase 2 study data announced, which suggest that the combination of VBI-2601 and an HBV siRNA has the potential to be a"
204,VBI Vaccines,2023-04-25,VBI Vaccines Appoints Vaughn Himes to Board of Directors,https://www.vbivaccines.com/press-releases/vbi-vaccines-appoints-vaughn-himes-to-board-of-directors/,204,204,"Vaughn Himes, Ph.D., Chief Technical Officer of Seagen Inc., has joined VBI’s Board of Directors. Dr. Himes has a 30+-year successful track record in biotechnology strategic direction and change management. VBI is uniquely positioned among its peer group with a commercial product, a fully owned GMP (Good Manufacturing Practice) facility, and a proprietary technology platform with promising and diversified development-stage candidates."
205,VBI Vaccines,2023-04-04,"VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split",https://www.vbivaccines.com/press-releases/increased-focus-on-hepatitis-b-organizational-changes-and-reverse-stock-split/,205,205,VBI Vaccines Inc. (Nasdaq: VBIV) (VBI) today announced plans to focus the Company’s efforts on the fight against hepatitis B (HBV) The company intends to reduce its internal workforce by 30-35% – a reduction which is expected to begin in April and complete by the end of June 2023. VBI will effect a 1-for-30 reverse stock split of its issued and outstanding common shares.
206,VBI Vaccines,2023-03-13,VBI Vaccines Reports Full Year 2022 Financial Results,https://www.vbivaccines.com/press-releases/2022-results/,206,206,"VBI Vaccines Inc. (Nasdaq: VBIV) (VBI) announced financial results for the year ended December 31, 2022. Access to PreHevbrio [Hepatitis B Vaccine (Recombinant)] continues to broaden in the U.S. and beyond, with additional approvals received in 2022 in Europe and Canada."
207,Vedanta Biosciences,2024-03-06,Vedanta Biosciences to Host Investor Meetings at the Leerink Partners 2024 Global Biopharma Conference,https://www.vedantabio.com/news-media/press-releases/detail/3098/vedanta-biosciences-to-host-investor-meetings-at-the,207,207,"Vedanta Biosciences will host investor meetings at the Leerink Partners 2024 Global Biopharma Conference being held in Miami, FL from Monday, March 11 through Wednesday, March 13, 2024. The company’s pipeline includes clinical-stage product candidates being evaluated for the prevention of recurrent C. difficile infection and inflammatory bowel diseases."
